{"Title": ["BioMarin To Participate In Goldman Sachs Global Healthcare Conference; Webcast At 2:10 PM ET", "How Biotech Companies Are Valued", "BioMarin To Participate In Jefferies Virtual Healthcare Conference At 4:00 PM ET", "2 Best Biotech Stocks to Buy Right Now", "Nasdaq 100 Movers: ATVI, PYPL", "BioMarin, DiNAQOR To Develop Gene Therapies For Rare Genetic Cardiomyopathies", "Biomarin Pharma Q1 20 Earnings Conference Call At 4:15 PM ET", "BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020", "BioMarin To Participate In Goldman Sachs Global Healthcare Conference; Webcast At 2:10 PM ET", "EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q1 Earnings Report", "Biomarin Pharmaceutical Q1 20 Earnings Conference Call At 4:15 PM ET", "Look Under The Hood: QQXT Has 10% Upside", "Is BioMarin Pharmaceuticals Stock a Buy?", "Notable Two Hundred Day Moving Average Cross - BMRN", "30 Top Stocks and Funds to Beat the COVID-19 Bear Market", "3 Top Biotech Stocks to Buy Now", "Biomarin Pharmaceutical Inc (BMRN) Q1 2020 Earnings Call Transcript", "Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday", "Why These Drug Stocks Soared Today", "Why BioMarin Pharmaceutical Inc. Stock Is Fading Today", "Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday", "Biomarin Pharmaceutical Inc (BMRN) Q4 2019 Earnings Call Transcript", "BioMarin Expects To Be Profitable In FY20; Revenue To Rise 14%-20%", "Biomarin Pharmaceutical Inc. Q4 adjusted earnings of -$ per share", "Implied VUG Analyst Target Price: $203", "First Week of October 16th Options Trading For BioMarin Pharmaceutical (BMRN)", "BioMarin's Novel Treatment Promises to Disrupt Competitors", "Noteworthy Friday Option Activity: GLUU, BMRN, SEAS", "Nasdaq 100 Movers: ALGN, BMRN", "FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review", "Why Invitae's Q4 Results Failed to Wow Investors", "Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?", "Biomarin Pharma Q4 19 Earnings Conference Call At 4:30 PM ET", "Add Up The Parts: FBT Could Be Worth $182", "3 Top Biotech Picks for 2020", "Notable Friday Option Activity: DOCU, BMRN, BHVN", "BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy", "3 Healthcare Stocks That Are Coming Back to Life", "Biomarin Pharma To Present At J.P. Morgan Conference; Webcast At 10:30 AM ET", "These 3 Biotech Stocks Could Be Top Stocks in 2020", "Interesting BMRN Put And Call Options For March 20th", "3 Best Stocks for 2020: The Race Is On", "Analysts See 11% Upside For The Holdings of BBH", "AXSM Again Proves It Is Awesome, MIRM Leaps To $22, WVE Doesn't Go The Distance", "BioMarin: Vosoritide Phase 3 Study Shows Positive Results - Quick Facts", "Are These Biotech Companies Buyout Candidates? Deal Or No Deal?", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Notable Thursday Option Activity: FGEN, BMRN, ESTC", "Here's Why BioMarin Pharmaceutical Leapt 10.2% in November", "Better Buy: Editas Medicine or Sangamo Therapeutics?", "These 3 \u201cStrong Buy\u201d Healthcare Stocks Have 40% Upside \u2014 Or More, Says Cowen", "Implied QQXT Analyst Target Price: $62", "2 Beaten-Down Biotech Stocks That Could Make You Rich", "3 Reasons BioMarin Pharmaceutical Stock Is a Buy Right Now", "Biomarin Pharmaceutical Inc (BMRN) Q3 2019 Earnings Call Transcript", "Why Has Alnylam's Stock Gained 25% In The Last Two Weeks", "Biomarin Pharmaceutical Q3 19 Earnings Conference Call At 4:30 PM ET", "Nasdaq 100 Movers: NFLX, ISRG", "2 High-Growth Stocks to Buy Right Now", "December 20th Options Now Available For BioMarin Pharmaceutical (BMRN)", "November 15th Options Now Available For BioMarin Pharmaceutical (BMRN)", "Biomarin Pharma To Present At Morgan Stanley Conference; Webcast At 8:35 AM ET", "Notable Friday Option Activity: BIIB, BMRN, EL", "Biomarin Pharmaceutical Inc. Q3 adjusted earnings Beat Estimates", "Biomarin Pharmaceutical Inc (BMRN) Q2 2019 Earnings Call Transcript", "Shake-Up in Big Weed", "Analysts Predict 29% Upside For The Holdings of IBB", "3 Top Biotech Stocks to Buy in July", "Here's Why Sangamo Therapeutics Is Surging Today", "The Math Shows EQAL Can Go To $37", "3 Top Growth Stocks to Buy in June", "BioMarin's Roller Coaster Continues", "Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?", "How BioMarin May Revolutionize the Hemophilia Treatment Market", "What Happened in the Stock Market Today", "Health Care Sector Update for 05/28/2019: KZR,TEVA,TRXC,BMRN", "Noteworthy Tuesday Option Activity: BHVN, BMRN, ASH", "Health Care Sector Update for 05/28/2019: TEVA,TRXC,BMRN", "Health Care Sector Update for 05/28/2019: TRXC, QTNT, BMRN, JNJ, PFE, ABT, MRK, AMGN", "September 20th Options Now Available For BioMarin Pharmaceutical (BMRN)", "3 Big Biotech Stocks That Warren Buffett Might Like", "Noteworthy Wednesday Option Activity: BPMC, BMRN, PGR", "Analysts Expect QQEW Will Reach $72", "BioMarin Isn't a \"Gene Therapy Company\"", "Biomarin Pharmaceutical Inc (BMRN) Q1 2019 Earnings Call Transcript", "Biomarin Pharmaceutical Inc. Q1 adjusted earnings of -$ per share", "Biomarin Pharmaceutical Q1 19 Earnings Conference Call At 4:30 PM ET", "BioMarin Reports Positive Data From Valoctocogene Roxaparvovec Study", "3 Big Biotech Stocks That Warren Buffett Might Like", "Nasdaq 100 Movers: EA, SYMC", "Nasdaq 100 Movers: EA, SYMC", "Does Sangamo Have the Best Gene Therapy Program Now?", "S&P Fights Past Growth Concerns to Reclaim 2800", "3 Stocks to Buy Ahead of the Next Market Crash", "Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?", "Nasdaq 100 Movers: BMRN, QCOM", "Boeing Keeps Dow from Joining Rally", "New Strong Sell Stocks for March 7th", "How The Pieces Add Up: QQEW Targets $69", "Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up", "2 More Gene Therapy Stocks on Big Pharma's Buyout Radar", "BioMarin Revenue Slips, but Big Picture Looks Dandy", "Nasdaq 100 Movers: INTU, BMRN", "New Strong Sell Stocks for March 18th", "Roche 'steps up' for gene therapy with $4.3 bln Spark bet", "Roche bets $4.3 bln on Spark in gene therapy move", "Roche to buy gene therapy specialist Spark in $4.3 bln deal", "BioMarin Pharmaceutical Inc. (BMRN) Q4 2018 Earnings Conference Call Transcript", "BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline", "Earnings Reaction History: BIOMARIN PHARMA, 37.5% Follow-Through Indicator, 1.8% Sensitive", "After-Hours Earnings Report for February 21, 2019 : INTU, KHC, BIDU, ED, HPE, SBAC, PBA, BMRN, KEYS, DXCM, ATUS, LNT", "Market Close Report: NASDAQ Composite index closes at 7,554.46 up 26.91 points", "Catalyst Pharma sees net price of drug, once free, topping $300,000", "Is Sangamo's Gene-Editing Approach a Bust?", "BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA", "3 Gene Therapy Stocks With Huge Catalysts in 2019", "Notable Thursday Option Activity: IAC, ENVA, BMRN", "Is BioMarin Pharmaceutical Stock a Bargain?", "Why Sarepta Therapeutics Stock Is Starting to Shine Again", "BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth", "BMRN Makes Bullish Cross Above Critical Moving Average", "BioMarin To Present At J.P. Morgan Conference; Webcast At 11:30 AM ET", "Analysts Anticipate 21% Upside For NTSX", "Noteworthy Thursday Option Activity: THRM, WTW, BMRN", "BioMarin Pharmaceutical is Now Oversold (BMRN)", "Nasdaq 100 Movers: WDAY, NTES", "Notable Wednesday Option Activity: GCO, BMRN, NBIX", "5 Biotech Stocks That Could Face M&A Next!", "Why Catalyst Pharmaceuticals Stock Is Sinking Today", "Sarepta Stock More Than Doubles This Year So Far: Here's Why", "Market Votes for Clarity", "Analysts Anticipate NTSX To Hit $28", "BioMarin Keeps on Pace for Its $2 Billion Goal", "Health Care Sector Update for 10/26/2018: OMCL,BMRN,RDY,SGYP", "Biomarin Pharmaceutical Inc (BMRN) Q3 2018 Earnings Conference Call Transcript", "5 Top Drug/Biotech Merger & Acquisition Targets for 2019", "BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates", "Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up", "After-Hours Earnings Report for October 25, 2018 : AMZN, GOOGL, INTC, GILD, SYK, FTV, DFS, DLR, RSG, CERN, FE, BMRN", "Dow, S&P Now in the Red for 2018", "BioMarin Pharmaceutical (BMRN) Q3 Earnings Preview: What to Watch Ahead of the Release", "NASDAQ Ends Losing Skid as Tech Rebounds", "Market Close Report: NASDAQ Composite index closes at 7,788.45 down -91.06 points", "Health Care Sector Update for 10/26/2018: BMRN,RDY,SGYP", "Dow All Alone in Record Territory", "Sum Up The Pieces: QQEW Could Be Worth $72", "First Week of November 16th Options Trading For BioMarin Pharmaceutical (BMRN)", "Stocks Stall Ahead of Hike", "Noteworthy Friday Option Activity: BMRN, ADP, AMCX", "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?", "Sluggish Start to September", "3 Biotech Stocks With Virtual Monopolies", "Market Close Report: NASDAQ Composite index closes at 7,821.01 up 4.68 points", "3 Tough-Luck Tumbles in Healthcare: Are They Buys?", "Is Spark Therapeutics a Bad News Buy?", "Notable Thursday Option Activity: MO, BMRN, DE", "What's Next for Spark Therapeutics", "BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%", "Nasdaq 100 Movers: XRAY, BMRN", "Analysts Predict 10% Gains Ahead For The Holdings of DWPP", "BioMarin (BMRN) Q2 Earnings Miss Estimates, Revenues Beat", "After-Hours Earnings Report for August 2, 2018 : EOG, ATVI, AIG, ED, CERN, MSI, FLT, ANET, PBA, CBS, BMRN, SEP", "Drug Stock Q2 Earnings Releases on Aug 2: ZTS, REGN & More", "BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?", "Look Under The Hood: QQEW Has 12% Upside", "Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III", "BioMarin Pharmaceutical Sets Its Sights on $2 Billion", "Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns", "The Math Shows QQEW Can Go To $70", "BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%", "BioMarin Begins Pediatric Study on Achondroplasia Candidate", "Nasdaq 100 Movers: ADBE, BMRN", "3 Biotech Stocks Up in the Past Month on Industry Turnaround", "Market Close Report: NASDAQ Composite index closes at 7,746.38 down -14.66 points", "18 Stocks That Could Be Takeover Targets", "Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns", "3 Biotech Stocks Up in the Past Month on Industry Turnaround", "10 Hot Stock Picks for a Summer Rally", "5 Biotech Stocks to Boost Your Portfolio\u2019s Health This Year", "5 Biotech Stocks to Boost Your Portfolio's Health This Year", "Catalyst's Fridapse Gets Priority Review by FDA, Shares Up", "Noteworthy Friday Option Activity: BMRN, ATHN, BA", "Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod", "Here's Why Sarepta is Up More Than 60% So Far This Year", "Which Is the Best Hemophilia Stock to Buy Now?", "This Rare-Disease Biotech Scores an Important Win", "BioMarin's Palynziq Gets FDA Approval for Phenylketonuria", "Nasdaq 100 Movers: ROST, BMRN", "Market Close Report: NASDAQ Composite index closes at 7,433.85 up 9.42 points", "Allergan Recalls Taytulla Oral Contraceptives, Stock Down", "A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker", "Nasdaq 100 Movers: BMRN, MU", "Health Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRN", "BioMarin Begins Mid Stage Study on Gene Therapy Candidate", "Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y", "BMRN Makes Bullish Cross Above Critical Moving Average", "BioMarin Cruises While It Waits on Seventh Approval", "Health Care Sector Update for 05/25/2018: BMRN,RMTI,ALXN,EVFM", "Implied IWF Analyst Target Price: $157", "What's in the Cards for BioMarin (BMRN) in Q1 Earnings?", "Catalyst Enrolls First Patient in Phase III Firdapse Study", "The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte", "Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug", "Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus", "Pharma M&A Active This Week: 4 Potential Buyout Targets", "BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat", "Market Close Report: NASDAQ Composite index closes at 6,950.34 up 35.23 points", "Catalyst (CPRX) Up on New Drug Application for Firdapse", "BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod", "5 Biotech Stocks With Amazing Pipelines", "DWPP's Underlying Holdings Could Mean 15% Gain Potential", "BioMarin Pharmaceutical (BMRN) Down 3.1% Since Earnings Report: Can It Rebound?", "BioMarin Turns a Profit (on an Adjusted Basis)", "Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 7,140.25", "BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat", "Market Close Report: NASDAQ Composite index closes at 7,337.39 up 127.30 points", "Earnings Reaction History: BioMarin Pharmaceutical, 33.3% Follow-Through Indicator, 2.1% Sensitive", "After-Hours Earnings Report for February 22, 2018 : INTU, HPQ, HPE, EIX, ES, MELI, BMRN, PBA, LNT, NDSN, OLED, HLF", "What to Expect From BioMarin (BMRN) This Earnings Season?", "Catalyst Gets Positive FDA Advise on Firdapse NDA Refiling", "Vertex (VRTX) & Other Drug Stocks with FDA Catalysts this February", "First Week of October 19th Options Trading For BioMarin Pharmaceutical (BMRN)", "Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017", "Why This Gene Therapy Pioneer Crashed 29.8% in December", "Surging Earnings Estimates Signal Good News for BioMarin Pharmaceutical (BMRN)", "What Drives Catalyst Pharmaceuticals Above 250% This Year?", "Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo", "BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA", "Notable ETF Outflow Detected - XT, CTSH, MELI, BMRN", "FBT's Holdings Imply 17% Gain Potential", "Here's Why Sangamo Therapeutics Inc. Stock Soared 438% in 2017", "New Gene Therapies Could Change Hemophilia Forever", "The FDA Just Blessed A Hemophilia Trial From This Biotech", "Alnylam Gets Some Welcome News", "5 Biotech Buyout Candidates for 2018", "Spark Therapeutics Stock Plunges on Hemophilia Therapy Data", "BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%", "BioMarin's (BMRN) Gene Therapy Enters First Phase III Study", "Why BioMarin Pharmaceutical Inc. Stock Is Surging Today", "Nasdaq 100 Movers: ORLY, BMRN", "NASDAQ Composite Index closes up 27.24 points for the week, rising for the 4th straight day", "Here's Why Sarepta Stock is Up More Than 70% in 6 Months", "10 Blockbuster Drugs of the Future for Big Pharma Stocks", "Catalyst (CPRX) Reports Positive Phase III Data on Firdapse", "Catalyst Initiates Phase II Study for Pipeline Drug Firdapse", "Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today", "Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease", "BioMarin Pharmaceutical is Now Oversold (BMRN)", "BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal", "If Celgene Buys This Biotech, Investors Should Win Big-Time", "BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised", "Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised", "Noteworthy Thursday Option Activity: ETSY, AZO, BMRN", "Analysts Anticipate 21% Upside For The Holdings of BBH", "Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease", "BioMarin Pharmaceutical is Now Oversold (BMRN)", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,624.22.", "BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA", "Noteworthy Wednesday Option Activity: BMRN, SALT, ABT", "How Spark's Gene Therapy Win Could Also Be A Boon For These Biotechs", "Interesting BMRN Put And Call Options For December 15th", "What's in Store for BioMarin (BMRN) This Earnings Season?", "Nasdaq 100 Movers: JD, BMRN", "Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook", "Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?", "BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA", "The Math Shows FBT Can Go To $140", "BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?", "BioMarin Presents Interim Data on BMN 250 from Phase I/II", "Here's Why Sarepta Stock is Up More Than 60% So Far in 2017", "Nasdaq 100 Movers: JD, BMRN", "BioMarin (BMRN) in Focus: Stock Moves 5.6% Higher", "Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update", "BioMarin's Pegvaliase BLA Granted Priority Review by the FDA", "These 3 Stocks Look Expensive but Are Actually Cheap", "3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical Inc. (BMRN) and Mondelez International Inc (MDLZ)", "Sarepta's Golodirsen Positive in DMD Study, Shares Soar", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Analysts Forecast 10% Gains Ahead For VXF", "BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter", "BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates", "Is Zoetis (ZTS) Poised for a Beat This Earnings Season?", "Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?", "Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings?", "Relative Strength Alert For BioMarin Pharmaceutical", "Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?", "Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View", "Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why", "Sarepta & BioMarin Settle Patent Litigation on Exon Skipping", "Market Close Report: NASDAQ Composite index closes at 6,314.43 up 1.96 points", "Wall Street\u2019s 5 Hottest Biotech Stocks Right Now", "The Math Shows BBH Can Go To $140", "Why Earnings Season Could Be Great for BioMarin (BMRN)", "Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More", "3 Reasons Why Gilead Sciences Shouldn't Buy Vertex Pharmaceuticals", "BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase", "3 Pivotal Drug Trials to Watch for Explosive Potential", "Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?", "Interesting BMRN Put And Call Options For August 18th", "BioMarin (BMRN) in Focus: Stock Moves 7% Higher", "Shire Completes NDA Filing for Hemophilia Drug with FDA", "Sum Up The Pieces: BBH Could Be Worth $138", "BioMarin's (BMRN) Brineura Approved by European Commission", "Health Care Sector Update for 06/01/2017: BMRN", "Ultragenyx Receives Priority Review for rhGUS from FDA", "Why Sangamo Therapeutics Inc. Jumped Higher Today", "BioMarin Pharmaceutical Breaks Below 200-Day Moving Average - Notable for BMRN", "7 Reasons Why Prescription Drug Prices Are Extremely Expensive", "BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?", "Sum Up The Pieces: BBH Could Be Worth $138", "BioMarin's (BMRN) Brineura Approved by European Commission", "After-Hours Earnings Report for May 4, 2017 : ATVI, MNST, ED, CBS, BMRN, MSI, MTD, MRO, PBA, MELI, ANET, Y", "Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update", "What Lies Ahead for Stericycle (SRCL) this Earnings Season?", "Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death", "BioMarin Pharmaceutical Inc. Moves Toward Profitability", "BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up", "Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug", "Nasdaq 100 Movers: MU, BMRN", "Notable Monday Option Activity: AA, VLO, BMRN", "Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed", "Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?", "6 FDA Events to Watch Out for in May 2017", "BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?", "Implied IYH Analyst Target Price: $171", "4 FDA Decisions to Watch Out for in Apr 2017", "4 Drug Stocks With Big News Coming in April", "Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?", "Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse", "5 Drug Stocks That Could Be Big Winners this Earnings Season", "Commit To Purchase BioMarin Pharmaceutical At $70, Earn 8.1% Using Options", "Repros (RPRX) Q4 Earnings: What's in Store for the Stock?", "Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?", "Inovio (INO): What's in the Cards this Earnings Season?", "BioDelivery (BDSI): What's in Store this Earnings Season?", "What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?", "Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?", "BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA", "Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals", "Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?", "Market Close Report: NASDAQ Composite index closes at 5,861.90 up 16.59 points", "BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster", "BioMarin Pharmaceutical Breaks Below 200-Day Moving Average - Notable for BMRN", "BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat", "After-Hours Earnings Report for February 23, 2017 : BIDU, HPE, INTU, BMRN, PBA, GPS, MELI, LNT, SPLK, JWN, WPC, LYV", "Analysts Expect BBH Will Reach $134", "Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising", "3 Biotech Stocks You May Be Overlooking", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.", "BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?", "Can Wright Medical (WMGI) Surprise Investors in Q4 Earnings?", "LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock?", "What's in Store for ImmunoGen (IMGN) this Earnings Season?", "Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More", "Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?", "Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?", "Teva (TEVA) Q4 Earnings: What's in Store for the Stock?", "5 Great Biotech Stocks to Buy Now", "BioMarin's Hemophilia Candidate Included in PRIME Initiative", "BioMarin Pharmaceutical (BMRN) Shares Cross Above 200 DMA", "Is BioMarin (BMRN) Well Poised for Growth in 2017?", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "BioMarin Pharmaceutical Breaks Above 200-Day Moving Average - Bullish for BMRN", "Top Stocks to Buy Now That the 21st Century Cures Act Has Passed", "Biotech Investing: 3 Bold Predictions for 2017", "The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen", "3 Overlooked Drug Stocks to Watch Out for in 2017", "BioMarin (BMRN) Raised to Buy: Should You Add the Stock?", "3 Precision Medicine Stocks to Buy in January", "Look Under The Hood: PXMG Has 10% Upside", "Market Close Report: NASDAQ Composite index closes at 5,380.68 down -5.67 points", "5 Biotech Stocks George Soros Is Buying", "Analysts Anticipate QLD Will Reach $94", "Merck KGaA's (MKGAF) Q3 Earnings and Sales Increase Y/Y", "Nasdaq 100 Movers: BMRN, JD", "Why BioMarin (BMRN) Could Be Positioned for a Surge", "3 Growth Stocks You Should Avoid in 2017", "Nasdaq 100 Movers: BMRN, NFLX", "Market Close Report: NASDAQ Composite index closes at 5,380.68 down -5.67 points", "Why These Biotechs Are Soaring Today", "BMRN Crosses Above Key Moving Average Level", "BioMarin's Stock Tumbled in October. Is It Now a Buy?", "Weighing The Week Ahead: Is It Finally Time For Clarity?", "Nasdaq 100 Movers: SYMC, ALXN", "Stock Exchange: Is Post-Election Technical Analysis Useful?", "Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million of Shares", "ImmunoGen (IMGN) Reports Wider-than-Expected Loss", "BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline", "AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates", "BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus", "United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss", "Agenus (AGEN) Reports Wider-than-Expected Loss in Q3", "Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y", "Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y", "McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View", "Seattle Genetics (SGEN) Loss Narrower than Expected in Q3", "Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook", "Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View", "Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View", "The Medicines Co. (MDCO) Q3 Loss Narrower than Expected", "Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3", "ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%", "Alexion (ALXN) Q3 Earnings Lag, Revenues Tops; Lifts View", "Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q2", "Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag", "Vertex's (VRTX) Q3 Loss Wider than Expected, Sales Miss", "Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View", "Lilly (LLY) Misses on Q3 Earnings, Sales; Animal Health Hurts", "Bayer (BAYRY) Beats on Q3 Earnings, Lifts 2016 Guidance", "ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%", "Bristol-Myers's (BMY) Opdivo Under Priority Review by FDA", "Merck Gets FDA Approval for Investigational Drug Zinplava", "Commit To Buy BioMarin Pharmaceutical At $65, Earn 8.6% Using Options", "Alkermes Depression Candidate Positive in Phase III Study", "How The Parts Add Up: QUS Targets $69", "Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact", "Inovio Stock Down on FDA Hold on VGX-3100 Phase III Study", "Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma", "AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted", "The Medicines Co. Reports Positive Phase II Data on PCSK9si", "3 Top Stocks for Your Roth IRA", "J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales", "Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia", "Alexion Graft-Versus-Host Disease Drug Wins Orphan Status", "Allergan's Belkyra Gets Swedish Approval for Double Chin", "Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion", "Precious Metal Outlook", "David Rolfe Comments on TreeHouse Foods", "BioMarin Issues Encouraging Update on Hemophilia A Drug", "Sunesis Submits Response to Questions on Leukemia Drug", "OncoGenex Cancer Drug Fails in Phase III Study, Stock Down", "Tetraphase Begins Phase III Dosing of Antibiotic Candidate", "AMAG Issues Encouraging Updates on Makena & Feraheme", "Supernus (SUPN) Reports Encouraging Data from ADHD Study", "BMRN Crosses Below Key Moving Average Level", "Market Close Report: NASDAQ Composite index closes at 5,239.02 down -7.77 points", "3 Biotechs Most Likely to Be Acquired", "Catabasis Presents Data from DMD study on Edasalonexent", "Alexion Presents New Long-Term Phase III Data on Kanuma", "What Makes Vertex Pharmaceuticals (VRTX) a Strong Sell?", "Is Sarepta Therapeutics Still a Risky Bet?", "Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc", "Nasdaq 100 Movers: ALXN, BMRN", "Nasdaq 100 Movers: BMRN, BBBY", "Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?", "Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug", "2 Biotech Stocks that Turned $8,000 into over $250,000", "New Strong Buy Stocks for October 6th", "BioMarin's (BMRN) Brineura Review Period Extended by FDA", "Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled", "Nasdaq 100 Movers: VIAB, INCY", "Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today", "We Did The Math PTH Can Go To $54", "Why You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock", "7 Battered Biotech Stocks to Buy", "Notable ETF Outflow Detected - PBE, INCY, BMRN, REGN", "BioMarin's (BMRN) Brineura Review Period Extended by FDA", "Solid BioMarin Pharmaceutical Inc. Earnings, More to Come", "Health Care Sector Update for 08/09/2016: NVRO,HIIQ,BMRN", "Nasdaq 100 Movers: NCLH, MCHP", "Why Wayfair Inc (W), BioMarin Pharmaceutical Inc. (BMRN) and Norwegian Cruise Line Holdings Ltd (NCLH) Are 3 of Today\u2019s Worst Stocks", "Health Care Sector Update for 08/09/2016: IPXL,HIIQ,BMRN", "Why BioMarin Pharmaceutical Inc. Stock Rose 22.2% in July", "The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen", "Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales", "Earnings Reaction History: BioMarin Pharmaceutical, 50.0% Follow-Through Indicator, 3.1% Sensitive", "After-Hours Earnings Report for August 4, 2016 : KHC, PCLN, ATVI, ED, LNKD, BMRN, MHK, FLT, SYMC, MSI, FRT, LBTYA", "5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More", "Is a Surprise Coming for BioMarin Pharmaceutical (BMRN) This Earnings Season?", "Will AVEO (AVEO) Pull a Surprise This Earnings Season?", "Can GW Pharmaceuticals (GWPH) Surprise in Q3 Earnings?", "BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped", "BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?", "Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?", "Sam Isaly Swaps 3 Health Care Stocks in Second Quarter", "Pfizer (PFE) Likely to Beat Earnings in Q2 Again", "BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%", "Notable ETF Inflow Detected - XBI, IONS, TSRO, BMRN", "Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?", "Will ImmunoGen (IMGN) Disappoint Again on Q4 Earnings?", "Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?", "Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?", "Trade of the Day: Breakout Could Send BMRN Stock 25% Higher", "Can The Uptrend Continue for with BioMarin Pharmaceutical (BMRN)?", "Earnings Estimates for These 3 Biotech Giants Should Be Heading Lower -- Here's Why", "Nasdaq 100 Movers: VIAB, NTES", "Why BioMarin's Shares Tumbled 11% in June", "ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?", "Vertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store?", "Amgen (AMGN) May Beat Q2 Earnings: Will the Stock Gain?", "Nasdaq 100 Movers: CELG, BMRN", "Pre-Market Most Active for Jul 7, 2016 : WWAV, LYG, VRX, BAC, BLL, SAN^B, QQQ, BMRN, XIV, ROIC, VOD, FB", "Why AVG Technologies, EZCorp, and BioMarin Pharmaceutical Jumped Today", "Why BioMarin Pharmaceutical Inc. (BMRN), Western Digital Corp (WDC) and WhiteWave Foods Co (WWAV) Are 3 of Today\u2019s Best Stocks", "Noteworthy Thursday Option Activity: BWLD, CUDA, BMRN", "Catabasis' DMD Drug in Phase II Open-Label Extension Study", "Nasdaq 100 Movers: LLTC, BMRN", "Nasdaq 100 Movers: AAL, SYMC", "Why American Airlines Group Inc (AAL), BioMarin Pharmaceutical Inc. (BMRN) and Cavium Inc (CAVM) Are 3 of Today\u2019s Worst Stocks", "Noteworthy Thursday Option Activity: ANAC, CACC, BMRN", "Nasdaq 100 Movers: WFM, BMRN", "The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron", "4 Stocks That Crushed the Biotechnology ETF (IBB) This Week", "How Does Brexit Impact Healthcare Stocks?", "Sarepta Asked to Provide Dystrophin Data on Eteplirsen", "BioMarin Withdraws Kyndrisa Marketing Application in EU", "10 Biotech Stocks With Symptoms of Strong Growth", "Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View", "Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?", "Analysts Expect 19% Upside For QQXT", "Nasdaq 100 Movers: BMRN, DISCA", "BBH's Holdings Imply 25% Gain Potential", "Why Sarepta Therapeutics Inc. Is Up Big Today", "After-Hours Earnings Report for April 28, 2016 : AMZN, GILD, AMGN, BIDU, HIG, RSG, EXPE, ESS, BMRN, LNKD, SWKS, DLR", "Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN", "Should You Buy BioMarin Pharmaceutical (BMRN) Ahead of Earnings?", "Despite Pleas, FDA Panel Shuns Drug", "Alexion (ALXN) Q1 Earnings: What's in Store for the Stock?", "Celgene (CELG) Q1 Earnings: What's in Store for the Stock?", "BioMarin (BMRN) Reports Narrower-than-Expected Q1 Loss", "BioMarin (BMRN) Q1 Earnings: Stock Likely to Beat Estimates", "Amgen (AMGN) May Beat Q1 Earnings: Will the Stock Gain?", "Baxalta (BXLT) Q1 Earnings: Can the Stock Pull a Surprise?", "5 Biotech Stocks to Bet on This Earnings Season", "Bristol-Myers (BMY) Q1 Earnings: Can the Stock Surprise?", "Vertex (VRTX) to Report Q1 Earnings: Is a Surprise in Store?", "AbbVie (ABBV) Likely to Beat on Q1 Earnings: Stock to Gain?", "What's in Store for Keryx (KERX) this Earnings Season?", "7 Stocks to Buy Before Summer Arrives", "Nasdaq 100 Movers: MAT, CTXS", "Will Currency & Competition Hurt Lilly's (LLY) Q1 Earnings?", "Nasdaq 100 Movers: CHKP, BMRN", "Will MS Franchise Sales Boost Biogen's (BIIB) 1Q Earnings?", "Notable Tuesday Option Activity: BMRN, SEE, TOWN", "3 Ways Pfizer Can Improve Shareholder Value Without Allergan", "Glaxo (GSK) Q1 Earnings: What's in Store for the Stock?", "Why Sarepta Therapeutics Inc. Soared 44% Higher in March", "3 Drug Developers Pfizer Could Go After Now That the Allergan Deal Is Officially Dead", "Why Sarepta Therapeutics Surged 20% in Wednesday Trading?", "Analysts Anticipate MTUM Will Reach $81", "Nasdaq 100 Movers: ENDP, INCY", "The 5-Minute Guide to BioMarin Pharmaceutical Stock", "BioMarin (BMRN) BMN 270 Gets Orphan Drug Status in EU", "3 Beaten-Down Biotech Stocks You Can Buy Right Now", "Nasdaq 100 Movers: NCLH, BMRN", "BioMarin (BMRN) Down on Phase III Data on Pegvaliase", "Nasdaq 100 Movers: BMRN, ENDP", "Sarepta Up, DMD Drug Eteplirsen to Face FDA Panel in April", "Sarepta 4-Year Data Analysis Of Eteplirsen To Treat DMD", "What Awaits Merck KGaA (MKGAF) this Earnings Season?", "Sanofi/Genzyme Present Positive Pompe Disease Study Data", "Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation", "BioMarin Pharmaceutical Inc. Ratchets Up the Profitability Talk", "Health Care Sector Update for 03/02/2016: BMRN, EVDY, XTLB", "Nasdaq 100 Movers: ENDP, BMRN", "Nasdaq 100 Movers: INTU, BIDU", "BioMarin Incurs Loss in Q4, Misses Estimates, Gives '16 View", "Biotech Stock Roundup: PTCT Plunges on \"RTF\" from FDA, Radius Shoots Up on Amgen Data", "After-Hours Earnings Report for February 25, 2016 : BIDU, EOG, MNST, INTU, GG, MHK, BMRN, SBAC, DLR, ADSK, PANW, GPS", "BioMarin (BMRN) Presents Positive Data on Cerliponase Alfa", "BioMarin (BMRN) to Report Q4 Earnings: What's in Store?", "Nasdaq 100 Movers: VIAB, AKAM", "Will Teva (TEVA) Continue with its Earnings Streak in Q4?", "Sarepta Hits 52-Week Low; Eteplirsen Review Period Extended", "VXF, LNKD, INCY, BMRN: ETF Outflow Alert", "Why Sarepta Therapeutics Inc. Is Down Today", "Why Shares of Sarepta Therapeutics Inc. Collapsed in January", "An FDA Letter Caused PTC Therapeutics to Crash Today", "The Math Shows QQQ Can Go To $129", "Notable ETF Inflow Detected - VXF, LNKD, INCY, BMRN", "Will 2016 Be BioMarin Pharmaceutical's Best Year Yet?", "Biotech Stock Roundup: Sarepta Plunges on Briefing Documents, Acorda to Buy Biotie", "Nasdaq 100 Movers: BMRN, VIAB", "Sarepta Tanks, Eteplirsen Briefing Document Raises Concerns", "Midday Update: Stocks Free-Falling Following More Bad News Out of China, New Drop in Oil Prices", "Why Medivation, Inc. Shares Crashed 32% in January", "Sarepta Therapeutics Plummets 50% as FDA Rejects BioMarin's NDA For Duchenne Muscular Dystrophy", "Close Update: Stocks Close Lower For Third Straight Week as China, Oil Weighs", "Update: Sarepta Therapeutics Plummets on Muted FDA Briefing Ahead DMD Drug Review", "BioMarin's DMD Drug Kyndrisa Receives CRL from the FDA", "Nasdaq 100 Movers: BMRN, NTAP", "Why BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc, and ImmunoGen, Inc. Got Clobbered Today", "The FDA's Change of Heart Sends Sarepta Therapeutics' Shares Soaring in 2015", "Here's Why Sarepta Therapeutics Is Getting Crushed Today", "BioMarin Reveals Interim Data from Pompe Disease Study", "What Does 2016 Hold for Biotech Stocks?", "Sarepta's DMD Drug Eteplirsen to Face FDA Panel in January", "Nasdaq 100 Movers: NXPI, NCLH", "VXF, LNKD, INCY, BMRN: ETF Inflow Alert", "The Zacks Analyst Blog Highlights: Actelion, Amgen, Gilead, AbbVie and BioMarin", "Biotech Stock Roundup: KaloBios Removes CEO Shkreli, Actelion PAH Drug Approved", "3 Biotechs With Major Catalysts Incoming", "BioMarin's (BMRN) Kyndrisa Review Period Extended by FDA", "Nasdaq 100 Movers: VRSK, BMRN", "Why Shares of Catalyst Pharmaceuticals Soared Today", "Biotech Stock Roundup: Amgen Hikes First Quarter Dividend, ARIAD Lowers Iclusig Outlook", "PBE, BMRN, INCY, VRTX: Large Outflows Detected at ETF", "3 Stocks We're Ready to Sell", "Why a Failure By BioMarin Caused Sarepta's Shares to Spike 53% in November", "Nasdaq 100 Movers: CMCSA, AAL", "Sarepta Therapeutics: Discretion Is the Better Part of Valor", "Nasdaq 100 Movers: BMRN, GMCR", "Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug", "Pre-Market Most Active for Nov 25, 2015 : SUNE, SDRL, ALU, PBR, TVIX, DE, KBIO, XIV, MT, FB, AAPL, BMRN", "Health Care Sector Update for 11/25/2015: EPIX, BMRN, IPXL", "BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel", "BioMarin's Vimizim Gets NICE Recommendation in England", "The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros", "BioMarin's DMD Drug Faces Obstacles Tomorrow", "If You're in Your 50s, Consider Buying These Stocks", "3 Specialty-Drug Makers Trying to Spark Investor Interest -- Are They Buys?", "Why Sarepta Therapeutics Inc Is Soaring Today", "Pre-Market Most Active for Nov 20, 2015 : S, AZN, SRPT, MFG, MENT, NMBL, AUO, BMRN, UL, DEPO, KBIO, QQQ", "Health Care Sector Update for 11/20/2015: SRPT,BMRN,KBIO,APTO", "Notable Thursday Option Activity: GTY, BMRN, INVN", "BioMarin Down on FDA's Briefing Document on Kyndrisa", "Biotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni", "Nasdaq 100 Movers: BMRN, JD", "Sarepta Posts Wider-than-Expected Loss in Q3, Shares Down", "BioMarin Pharmaceutical Inc. Earnings: Pushing Toward Profitability", "BioMarin's Q3 Loss Narrower than Expected, Outlook Revised", "After-Hours Earnings Report for October 29, 2015 : SBUX, BIDU, LNKD, EA, BXP, BMRN, RSG, ESS, EXPE, FE, EMN, WU", "What Awaits BioMarin (BMRN) This Earnings Season?", "Sarepta's Long-Term Phase IIb Data on Eteplirsen Published", "Biotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni", "BioMarin's Drisapersen to be Reviewed by FDA's Committee", "PTC Therapeutics Presents Phase III Data on Translarna", "Why BioMarin Is Unfazed by Price-Gouging Proposals", "Noteworthy ETF Outflows: VXF, ILMN, UAL, BMRN", "Health Care Sector Update for 10/15/2015: KITE, BMRN, CRBP", "Sarepta Down, Eteplirsen Likely to Face FDA Panel in Jan", "3 Cancer Companies to Watch Closely in 2016", "BioMarin Presents Data on Vosoritide at Medical Meeting", "Catalyst Starts Congenital Myasthenic Syndromes Study", "Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?", "BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs", "Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar", "Why Sarepta Therapeutics Shares Are Soaring Today", "BioMarin (BMRN) Looks Good: Stock Adds 8.8% in Session", "How This Biotech Stock Hopes to Become More Than a One Trick Pony", "The Duchenne Muscular Dystrophy Patent Battle Continues", "Nasdaq 100 Movers: BMRN, INTC", "Bull of the Day: Medivation (MDVN)", "BMRN Crosses Below Key Moving Average Level", "BioMarin-Dr. Reddy's Agree to Settle Kuvan Patent Litigation", "Medivation Upgraded to Strong Buy, Perfect for Your Portfolio", "Noteworthy ETF Outflows: VXF, ILMN, BMRN, LNKD", "Nasdaq 100 Movers: MAT, WDC", "First Week of April 2016 Options Trading For BioMarin Pharmaceutical Inc. (BMRN)", "The Duchenne Muscular Dystrophy Race Is On", "The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure", "Noteworthy ETF Outflows: VXF, ILMN, BMRN, LNKD", "Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data", "Sarepta's DMD Drug Eteplirsen Gains FDA Priority Review", "Medivation to Gain Global Rights to BioMarin's Talazoparib", "Noteworthy ETF Inflows: VXF, ILMN, BMRN, LNKD", "3 Biotech Stocks That Could Be Buyout Targets", "United Therapeutics to Sell Priority Review Voucher to AbbVie", "BioMarin's Drisapersen Gets Rare Pediatric Disease Status", "Vanguard Extended Market ETF Experiences Big Inflow", "Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying?", "The 5 Most Expensive Drugs in the World in 2015", "Sarepta Posts Narrower-than-Expected Loss in Q2, Shares Up - Analyst Blog", "BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off", "BioMarin Q2 Loss Narrower than Expected, Maintains Outlook - Analyst Blog", "BioMarin Pharmaceuticals: Lumpy Sales Strike Again", "After-Hours Earnings Report for August 3, 2015 : AIG, ALL, GGP, BMRN, VNO, XL, CTRP, MCHP, CYH, MIC, OHI, UGI", "Will BioMarin Top Q2 Earnings Again on Vimizim Sales? - Analyst Blog", "Vanguard Extended Market ETF Experiences Big Outflow", "Why BioMarin Pharmaceutical (BMRN) Might Surprise This Earnings Season - Tale of the Tape", "Will Amgen (AMGN) Keep the Earnings Streak Alive in 2Q? - Analyst Blog", "Nasdaq 100 Movers: AVGO, REGN", "After Hours Most Active for Jul 24, 2015 : NTCT, QQQ, TDW, T, BMRN, AAPL, UTX^A, GE, NE, CSCO, PLCM, RDN", "BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog", "Noteworthy ETF Inflows: VXF, ILMN, LNKD, BMRN", "Catabasis Up on Fast Track Status for DMD Drug CAT-1004 - Analyst Blog", "The Zacks Analyst Blog Highlights: Celgene, Juno Therapeutics, Intercept, BioMarin and Sarepta - Press Releases", "Biotech Stock Roundup: Juno-Celgene In Immunotherapy Deal, BioMarin/Sarepta DMD Drugs Progress - Analyst Blog", "Sarepta Files Eteplirsen NDA, Secures $40M Debt Financing - Analyst Blog", "Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analyst Blog", "BioMarin DMD Drug Drisapersen Validated for EU Review - Analyst Blog", "The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases", "Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog", "Friday's ETF with Unusual Volume: PTH", "Health Care Sector Update for 06/19/2015: ACHC, BMRN, CYTK", "BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog", "Why BioMarin Pharmaceutical Inc. Shares Are Jumping Higher", "BioMarin's NDA for DMD Drug Drisapersen Accepted by FDA - Analyst Blog", "Health Care Sector Update for 06/18/2015: BMRN, DSCI, PARN", "Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall", "Thursday's ETF Movers: PBE, OIH", "Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge", "Use Options For a Chance To Buy BMRN at a 30% Discount", "BioMarin Seeks EU Approval for DMD Drug Drisapersen - Analyst Blog", "These 3 Ultra-Rare Diseases Are Utterly Terrifying", "Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views", "Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog", "Wednesday's ETF Movers: BBH, XOP", "Did BioMarin Bet on the Wrong Experimental DMD Drug?", "Merck KGaA-BioMarin's Kuvan may Undergo Label Update - Analyst Blog", "Uh-Oh! Billionaire George Soros Just Stepped on Another Biotech Landmine", "Sarepta to Finish Eteplirsen Regulatory Filing by Mid-15 - Analyst Blog", "Why Shares of Sarepta Therapeutics Skyrocketed Today", "Pfizer's Monstrous Clinical Pipeline Is Harboring 2 Hidden Gems", "Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity", "Will Suitors Line Up to Buy These Biotech Stocks Next?", "Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog", "BioMarin Pharmaceutical (BMRN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape", "Why Sarepta Therapeutics, Inc. Shares Soared Today", "Integra LifeSciences Tops Q1 Earnings, Revenues; View Up - Analyst Blog", "Acorda Posts 1Q Loss, Ampyra Generic Challenges in Focus - Analyst Blog", "Why I'm Buying Sarepta Therapeutics Stock", "Could This Dark Horse Be Pfizer Inc.'s Next Major Acquisition?", "Hot Issues on BioMarin Pharmaceutical Inc. Earnings Conference Call", "Sanofi Misses on Q1 Earnings by a Penny, Maintains Outlook - Analyst Blog", "Geron Q1 Loss In Line with Estimates, Restructuring on Track - Analyst Blog", "BioMarin Q1 Loss Narrower than Expected, '15 View Revised - Analyst Blog", "Earnings Reaction History: BioMarin Pharmaceutical, 33.3% Follow-Through Indicator, 2.8% Sensitive", "After-Hours Earnings Report for April 30, 2015 : GILD, V, AIG, PSA, LNKD, BMRN, SWKS, FLT, EMN, EXPE, WU, FMX", "Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog", "Zacks Rank #1 Additions for Wednesday - Tale of the Tape", "BioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog", "Can Expedia (EXPE) Pull a Surprise this Earnings Season? - Analyst Blog", "Will BioMarin (BMRN) Top Earnings Again on Vimzim Sales? - Analyst Blog", "Will United Therapeutics (UTHR) Miss This Earnings Season? - Analyst Blog", "10 Largest Companies by Market Cap in Biotech", "Why 1 Wall Street Firm Thinks BioMarin Pharmaceutical Inc. Could Soar", "3 Things to Watch as BioMarin Pharmaceutical Inc. Reports Earnings", "Midcap Growth Funds Power Ahead Amid March Malaise", "Sarepta Therapeutics Inc.'s CEO Exits: Is the Stock Now a Buy?", "Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog", "BioMarin Pharmaceutical (BMRN) Shows Strength: Stock Up 11.5% - Tale of the Tape", "Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets", "Why BioMarin Pharmaceutical Inc. Stock Is Surging Today", "Pre-Market Most Active for Mar 27, 2015 : BBRY, DOW, NVO, SAP, SDRL, OREX, XIV, SCAI, AAPL, TPVG, MT, BMRN", "BioMarin Pharmaceutical Larger Than S&P 500 Component Omnicom Group", "Friday Sector Leaders: General Contractors & Builders, Drugs", "Use Options For a Chance To Buy BMRN at a 28% Discount", "Profit takers active as biotech stalls", "Health Care Sector Update for 03/17/2015: CLDX, BMRN, ICPT", "BioMarin Pharmaceutical (BMRN) Jumps: Stock Moves Up 6.9% - Tale of the Tape", "Friday's ETF Movers: PBE, PIN", "3 Easy Ways to Fail When Investing in Biotech Stocks", "Friday's ETF Movers: FBT, XOP", "Did Researchers Just Discover a Functional Cure for Duchenne Muscular Dystrophy?", "Company News for February 27, 2015 - Corporate Summary", "Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog", "Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog", "Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog", "Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog", "BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog", "First Trust Health Care AlphaDEX Fund Experiences Big Inflow", "Use Options For a Chance To Buy BMRN at a 32% Discount", "Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog", "\"Profitability\" in Sight for BioMarin Pharmaceutical Inc.", "After-Hours Earnings Report for February 25, 2015 : CRM, AVGO, LB, BMRN, CXO, AR, WDAY, MDVN, ESV, TEG, CSGP, MELI", "Earnings Reaction History: BioMarin Pharmaceutical, 33.3% Follow-Through Indicator, 2.7% Sensitive", "After-Hours Earnings Report for February 25, 2015 : CRM, AVGO, LB, BMRN, CXO, AR, WDAY, MDVN, ESV, TEG, CSGP, MELI", "Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog", "Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog", "Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog", "Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog", "Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog", "Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog", "Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog", "Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog", "Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog", "Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog", "Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog", "Synthetic Biologics (SYN) Jumps: Stock Up 9.2% - Tale of the Tape", "AstraZeneca's Patent for Pulmicort Respules Found Invalid - Analyst Blog", "Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog", "Is This Company the Big Winner in Obama's Push for Precision Medicine?", "Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog", "Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog", "Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog", "Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog", "Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog", "Isis Pharma to Get $5M from Biogen - Analyst Blog", "Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog", "3 Biotech Stocks to Buy in February", "An $8 Billion Hedge Fund Bought This Extremely Risky Stock: Should You?", "Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog", "Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog", "Forget Marijuana Stocks: Here Are 3 Smarter Investments", "Health Care Sector Update for 01/22/2015: SHPG, NNVC, BMRN", "BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog", "State of the Union Address Investing Idea: Precision Medicine", "3 Warning Signs You've Invested in a Dangerous Biotech Stock", "BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog", "3 Biotech Stocks Focused on Curing Ultra-Rare Diseases", "Use Options For a Chance To Buy BMRN at a 24% Discount", "BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog", "IBB, GILD, REGN, BMRN: Large Inflows Detected at ETF", "Health Care Sector Update for 12/26/2014: BMRN,RNA,TPI,RHHBY", "Twitter's Favorite Biotech and Pharma Stocks", "5 Biotech Stocks to Buy for 2015", "3 Biotech Companies That Are Making Incredibly Smart Moves", "Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval - Analyst Blog", "Why Sarepta Therapeutics Inc. Stock Tumbled 15% in December", "BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog", "Midday Update: Stocks Grind Cautiously Higher Ahead of Economic Data, Gains In Europe", "Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share", "U.S. Stock Futures Buoyed by Upbeat German Data, Strength in Eurozone on Stimulus Talk", "Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year", "Closing Update: Stocks Extend Winning Streak to Third Day", "Health Care Sector Update for 11/26/2014: SRPT,RNA,BMRN,BDX,MRGE", "Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher", "Why Prosensa Holding NV Stock Skyrocketed", "Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News", "Health Care Sector Update for 11/24/2014: SYN,RNA,BMRN,TTHI,TTH.TO", "Gilead to Buy Knight Therapeutics' Priority Review Voucher - Analyst Blog", "Biotech: And Yet We've Just Begun...", "Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog", "Health Care Sector Update for 11/24/2014: TTPH,ATLN,RHHBY,RNA,BMRN,TTHI,TTH.TO", "Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October", "The 5 Most Expensive Drugs in the World", "Friday's ETF with Unusual Volume: BBH", "BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog", "BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company", "After-Hours Earnings Report for October 23, 2014 : MSFT, AMZN, CB, CERN, PFG, KLAC, SWN, EW, BMRN, TV, SRCL, ALTR", "Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog", "Is This Trend Making Gilead Sciences, Inc. Worry?", "January 2017 Options Now Available For BioMarin Pharmaceutical (BMRN)", "Notable Two Hundred Day Moving Average Cross - BMRN", "Merck KGaA's Kuvan Effective in Under-4 Year Olds - Analyst Blog", "Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor - Analyst Blog", "Can BioMarin Pharmaceutical (BMRN) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape", "7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know", "BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog", "Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again - Tale of the Tape", "Markets end July undecided", "BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up - Analyst Blog", "Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog", "Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera - Analyst Blog", "Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines - Analyst Blog", "Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales - Analyst Blog", "NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Repros Gets Additional FDA Guidance for Androxal - Analyst Blog", "Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent - Analyst Blog", "Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog", "Will Johnson & Johnson (JNJ) Beat this Earnings Season? - Analyst Blog", "BioMarin's Vimizim Gets Canadian Nod - Analyst Blog", "Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again - Tale of the Tape", "bluebird bio, Inc. (BLUE) in Focus: Stock Surges 10.24% - Tale of the Tape", "BioMarin's Pipeline Advances - Analyst Blog", "Loss at BioMarin Narrower Than Expected - Analyst Blog", "IBB, CELG, VRTX, BMRN: Large Inflows Detected at ETF", "Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog", "Good News for BioMarin - Analyst Blog", "BBH, ALKS, BMRN, ISIS: Large Outflows Detected at ETF", "Interesting BMRN Put And Call Options For August 16th", "Good News for Catalyst Pharma - Analyst Blog", "Narrower-than-Expected Loss at Catalyst Pharma - Analyst Blog", "BioMarin Pharmaceutical Larger Than S&P 500 Component Newmont Mining", "Interesting BMRN Put And Call Options For October 18th", "BioMarin Rises on Favorable CHMP Opinion - Analyst Blog", "Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog", "Strong 2014 Sales Guidance from BioMarin - Analyst Blog", "BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA", "BioMarin's Pipeline Encourages - Analyst Blog", "Biotech Stock Roundup: Sarepta Spikes on Data & Alnylam on Deal - Analyst Blog", "Pipeline Progress at BioMarin - Analyst Blog", "Sector Update: Healthcare Shares Flat Pre-Market; Catalyst Pharmaceutical Partners Rises 14% on Joint Study of Firdapse Tablets", "Sector Update: Healthcare", "Notice of Allowance Received by Alkermes - Analyst Blog", "BioMarin Pharmaceutical Inc. (BMRN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "FDA Clears BioMarin's Vimizim - Analyst Blog", "BioMarin Seeks Canadian Approval - Analyst Blog", "Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog", "Myriad, BioMarin Collaborate Again - Analyst Blog", "US Stocks: Short This Market With Care", "FDA Panel Positive on BioMarin's Vimizim - Analyst Blog", "BioMarin Shoots Up Ahead of FDA Panel - Analyst Blog", "BioMarin Pharmaceutical (BMRN) in Focus: Stock Jumps 7.7% - Tale of the Tape", "Myriad, Janssen Partner on BRACAnalysis - Analyst Blog", "BioMarin Seeks Canadian Approval - Analyst Blog", "Sector Update: Healthcare Higher Pre-Market; ImmunoGen Spikes 7% on Earnings", "Sector Update: Healthcare", "4 Pharma Stocks Set to Deliver Earnings Surprises - Earnings ESP", "Is Eli Lilly (LLY) Poised to Beat Earnings Estimates? - Analyst Blog", "Is Forest Labs (FRX) Poised to Beat Earnings Estimates? - Analyst Blog", "Good News for Catalyst Pharma's Pipeline - Analyst Blog", "Pre-Market Most Active for Nov 15, 2013 : TMUS, NOK, SMFG, BAC, VNDA, BMRN, PFE, MET, SLM, MHLD, AGNC, CSCO", "Encouraging Pipeline Data from BioMarin - Analyst Blog", "Pipeline Progress at BioMarin - Analyst Blog", "Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate", "Sector Update: Healthcare Flat to Higher Pre-Market; ISIS up 4%", "Sector Update: Healthcare", "Pre-Market Most Active for Sep 19, 2013 : RAD, NOK, ORCL, BMRN, P, SNY, ONXX, A, FSC, CSCO, FB, DRYS", "Pipeline Update from BioMarin - Analyst Blog", "BioMarin to Raise Funds - Analyst Blog", "Sector Update: Healthcare", "Catalyst Pharma Raises Funds - Analyst Blog", "FDA Designation for CPRX's Firdapse - Analyst Blog", "Narrower-Than-Expected Loss at BioMarin - Analyst Blog", "After-Hours Earnings Report for July 25, 2013 : AMZN, GILD, SBUX, MCK, CB, CERN, NEM, RSG, PFG, KLAC, BMRN, CBG", "BioMarin Stays Neutral - Analyst Blog", "BioMarin Files Vimizim MA in Brazil - Analyst Blog", "Healthcare Stocks Mixed Near Bell; BioMarin Pharma Climbing With Morquio A Treatment Set by FDA Advisory Review", "Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings", "BioMarin Widens Loss, Maintains View - Analyst Blog", "BioMarin Attains 52-Week High - Analyst Blog", "BioMarin Files CTA for BMN-190 - Analyst Blog", "BMRN Seeks US Approval of Vimizim - Analyst Blog", "Data on BioMarin's BMN-701 - Analyst Blog", "Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy", "Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News", "After-Hours Earnings Report for February 21, 2013 : AIG, HPQ, PSA, NEM, INTU, SWN, COG, JWN, SBAC, MHK, BMRN, TS", "Positive Data from BMRN's PKU-016 - Analyst Blog", "BioMarin Takes Over Zacharon - Analyst Blog", "BioMarin strategy looks for further gains", "Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN", "Good News for BioMarin - Analyst Blog", "Pre-Market Most Active for Nov 5, 2012 : BAC, QQQ, AAPL, BMRN, GFA, BHP, FB, UBS, RIG, NOK, ZNGA, INTC", "BioMarin Reports Wider Loss - Analyst Blog", "After-Hours Earnings Report for February 21, 2013 : AIG, HPQ, PSA, NEM, INTU, SWN, COG, JWN, SBAC, MHK, BMRN, TS", "Positive Data from BMRN's PKU-016 - Analyst Blog", "BioMarin Progresses with PEG-PA - Analyst Blog", "4 Biotech Stocks Ready to Explode", "BioMarin Loss Widens, Sales Climb - Analyst Blog", "After-Hours Earnings Report for August 1, 2012 : DOX, BMRN, APL, ALGT, ALEX, AAT, SAM, ATNI, AIN, ASI, AXTI, BALT", "Why volatility is key to trade in BioMarin", "BioMarin Reports Narrower Loss - Analyst Blog", "BioMarin to Raise Funds - Analyst Blog", "Myriad Inks Deal with Cephalon - Analyst Blog", "BioMarin Raised to Neutral - Analyst Blog", "Loss at BioMarin Wider Than Expected - Analyst Blog", "BioMarin Lowered to Underperform - Analyst Blog", "Zacks Bull and Bear of the Day Highlights: ProAssurance, BioMarin Pharmaceutical, Diebold, Vodafone and United Parcel Services - Press Releases", "Zacks #5 Rank Additions for Wednesday - Tale of the Tape", "BioMarin Prices Share Offering - Analyst Blog", "BioMarin's Facility Expansion Backed - Analyst Blog", "Pipeline Progress at BioMarin - Analyst Blog", "Facility Expansion at BioMarin - Analyst Blog", "Narrowing Down the List of Biotech ETFs to 2 We'd Recommend", "Qiagen Expands with New Deals - Analyst Blog"], "Elapsed Time": ["3 DAYS AGO", "5 DAYS AGO", "JUN 4, 2020", "JUN 1, 2020", "MAY 7, 2020", "MAY 3, 2020", "APR 30, 2020", "APR 30, 2020", "3 DAYS AGO", "APR 29, 2020", "APR 29, 2020", "APR 27, 2020", "APR 8, 2020", "APR 7, 2020", "APR 5, 2020", "APR 2, 2020", "APR 30, 2020", "MAR 16, 2020", "MAR 13, 2020", "MAR 12, 2020", "MAR 9, 2020", "FEB 27, 2020", "FEB 26, 2020", "FEB 26, 2020", "MAR 26, 2020", "FEB 26, 2020", "FEB 26, 2020", "FEB 21, 2020", "FEB 21, 2020", "FEB 20, 2020", "FEB 20, 2020", "JAN 28, 2020", "FEB 26, 2020", "JAN 21, 2020", "JAN 20, 2020", "JAN 17, 2020", "JAN 16, 2020", "JAN 15, 2020", "JAN 13, 2020", "JAN 11, 2020", "JAN 22, 2020", "JAN 6, 2020", "DEC 20, 2019", "DEC 16, 2019", "DEC 16, 2019", "DEC 14, 2019", "DEC 5, 2019", "DEC 5, 2019", "JAN 9, 2020", "DEC 4, 2019", "NOV 26, 2019", "NOV 20, 2019", "NOV 18, 2019", "NOV 11, 2019", "OCT 24, 2019", "OCT 24, 2019", "DEC 5, 2019", "OCT 23, 2019", "OCT 18, 2019", "OCT 17, 2019", "OCT 1, 2019", "SEP 19, 2019", "SEP 10, 2019", "AUG 16, 2019", "OCT 23, 2019", "AUG 2, 2019", "JUL 12, 2019", "JUL 11, 2019", "JUL 9, 2019", "JUL 8, 2019", "JUN 10, 2019", "JUN 9, 2019", "AUG 6, 2019", "MAY 31, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 28, 2019", "MAY 28, 2019", "JUN 3, 2019", "MAY 26, 2019", "MAY 15, 2019", "MAY 9, 2019", "MAY 1, 2019", "APR 26, 2019", "APR 25, 2019", "APR 25, 2019", "MAY 28, 2019", "MAY 26, 2019", "APR 8, 2019", "APR 8, 2019", "APR 3, 2019", "MAR 27, 2019", "MAR 25, 2019", "MAR 23, 2019", "APR 17, 2019", "MAR 13, 2019", "MAR 7, 2019", "MAR 7, 2019", "FEB 28, 2019", "FEB 26, 2019", "FEB 26, 2019", "FEB 25, 2019", "MAR 18, 2019", "FEB 25, 2019", "FEB 25, 2019", "FEB 25, 2019", "FEB 22, 2019", "FEB 22, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 25, 2019", "FEB 11, 2019", "FEB 9, 2019", "FEB 7, 2019", "FEB 3, 2019", "JAN 31, 2019", "JAN 14, 2019", "JAN 11, 2019", "FEB 14, 2019", "JAN 10, 2019", "JAN 7, 2019", "JAN 3, 2019", "JAN 3, 2019", "DEC 21, 2018", "DEC 21, 2018", "DEC 12, 2018", "JAN 10, 2019", "NOV 29, 2018", "NOV 23, 2018", "NOV 7, 2018", "NOV 2, 2018", "OCT 31, 2018", "OCT 26, 2018", "OCT 26, 2018", "DEC 10, 2018", "OCT 26, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 25, 2018", "OCT 18, 2018", "OCT 10, 2018", "OCT 5, 2018", "OCT 26, 2018", "OCT 3, 2018", "OCT 2, 2018", "SEP 26, 2018", "SEP 26, 2018", "SEP 21, 2018", "SEP 6, 2018", "SEP 5, 2018", "OCT 3, 2018", "AUG 20, 2018", "AUG 17, 2018", "AUG 17, 2018", "AUG 16, 2018", "AUG 15, 2018", "AUG 8, 2018", "AUG 7, 2018", "AUG 31, 2018", "AUG 3, 2018", "AUG 2, 2018", "AUG 1, 2018", "JUL 30, 2018", "JUL 30, 2018", "JUL 17, 2018", "AUG 7, 2018", "JUL 5, 2018", "JUN 28, 2018", "JUN 18, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUN 15, 2018", "JUL 10, 2018", "JUL 5, 2018", "JUN 5, 2018", "JUN 1, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 31, 2018", "JUN 15, 2018", "MAY 30, 2018", "MAY 29, 2018", "MAY 26, 2018", "MAY 26, 2018", "MAY 25, 2018", "MAY 25, 2018", "MAY 25, 2018", "MAY 30, 2018", "MAY 23, 2018", "MAY 22, 2018", "MAY 22, 2018", "MAY 16, 2018", "MAY 15, 2018", "MAY 7, 2018", "APR 27, 2018", "MAY 25, 2018", "APR 26, 2018", "APR 24, 2018", "APR 20, 2018", "APR 16, 2018", "APR 13, 2018", "APR 13, 2018", "APR 13, 2018", "APR 26, 2018", "APR 9, 2018", "APR 5, 2018", "MAR 29, 2018", "MAR 27, 2018", "MAR 26, 2018", "MAR 26, 2018", "FEB 26, 2018", "APR 12, 2018", "FEB 23, 2018", "FEB 23, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 20, 2018", "FEB 14, 2018", "JAN 31, 2018", "FEB 23, 2018", "JAN 9, 2018", "JAN 6, 2018", "JAN 5, 2018", "DEC 28, 2017", "DEC 27, 2017", "DEC 26, 2017", "DEC 22, 2017", "JAN 22, 2018", "JAN 9, 2018", "DEC 19, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 12, 2017", "DEC 20, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 11, 2017", "DEC 5, 2017", "NOV 30, 2017", "NOV 28, 2017", "NOV 22, 2017", "DEC 11, 2017", "NOV 17, 2017", "NOV 14, 2017", "NOV 1, 2017", "OCT 31, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 26, 2017", "NOV 20, 2017", "NOV 17, 2017", "NOV 14, 2017", "OCT 18, 2017", "OCT 18, 2017", "OCT 18, 2017", "OCT 13, 2017", "OCT 2, 2017", "OCT 23, 2017", "SEP 21, 2017", "SEP 20, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 7, 2017", "SEP 7, 2017", "SEP 25, 2017", "SEP 21, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 23, 2017", "SEP 7, 2017", "SEP 6, 2017", "AUG 14, 2017", "AUG 4, 2017", "AUG 3, 2017", "AUG 1, 2017", "JUL 31, 2017", "JUL 31, 2017", "AUG 21, 2017", "JUL 27, 2017", "JUL 20, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 17, 2017", "JUL 17, 2017", "JUL 12, 2017", "JUL 31, 2017", "JUL 5, 2017", "JUL 3, 2017", "JUL 3, 2017", "JUN 29, 2017", "JUN 28, 2017", "JUN 23, 2017", "JUN 22, 2017", "JUL 7, 2017", "JUN 6, 2017", "JUN 2, 2017", "JUN 1, 2017", "MAY 24, 2017", "MAY 12, 2017", "MAY 10, 2017", "JUN 9, 2017", "JUN 8, 2017", "JUN 6, 2017", "JUN 2, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 10, 2017", "MAY 9, 2017", "MAY 5, 2017", "APR 26, 2017", "APR 24, 2017", "APR 24, 2017", "APR 19, 2017", "MAY 1, 2017", "MAY 1, 2017", "APR 6, 2017", "APR 3, 2017", "APR 3, 2017", "APR 2, 2017", "MAR 28, 2017", "MAR 23, 2017", "APR 17, 2017", "MAR 15, 2017", "MAR 7, 2017", "MAR 7, 2017", "MAR 6, 2017", "MAR 6, 2017", "MAR 6, 2017", "MAR 6, 2017", "MAR 21, 2017", "MAR 1, 2017", "MAR 1, 2017", "FEB 27, 2017", "FEB 25, 2017", "FEB 24, 2017", "FEB 24, 2017", "FEB 23, 2017", "MAR 2, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 20, 2017", "FEB 17, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 13, 2017", "FEB 22, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 8, 2017", "FEB 7, 2017", "FEB 2, 2017", "FEB 1, 2017", "JAN 26, 2017", "FEB 10, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 6, 2017", "JAN 4, 2017", "JAN 3, 2017", "DEC 29, 2016", "DEC 27, 2016", "JAN 24, 2017", "NOV 23, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 15, 2016", "DEC 15, 2016", "NOV 29, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 6, 2016", "NOV 4, 2016", "NOV 11, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 31, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 31, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 27, 2016", "OCT 25, 2016", "OCT 24, 2016", "OCT 24, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 21, 2016", "OCT 25, 2016", "OCT 20, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 20, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 17, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 13, 2016", "OCT 12, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 13, 2016", "OCT 2, 2016", "SEP 28, 2016", "SEP 23, 2016", "SEP 22, 2016", "SEP 20, 2016", "SEP 20, 2016", "SEP 12, 2016", "OCT 6, 2016", "SEP 7, 2016", "SEP 7, 2016", "AUG 22, 2016", "AUG 22, 2016", "AUG 17, 2016", "AUG 16, 2016", "AUG 14, 2016", "SEP 8, 2016", "SEP 7, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 6, 2016", "AUG 12, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 4, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 3, 2016", "AUG 2, 2016", "AUG 5, 2016", "AUG 1, 2016", "AUG 1, 2016", "JUL 30, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 26, 2016", "AUG 2, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 25, 2016", "JUL 19, 2016", "JUL 19, 2016", "JUL 11, 2016", "JUL 9, 2016", "JUL 26, 2016", "JUL 25, 2016", "JUL 8, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 7, 2016", "JUL 8, 2016", "JUN 17, 2016", "JUN 16, 2016", "JUN 16, 2016", "JUN 16, 2016", "JUN 15, 2016", "JUN 13, 2016", "JUN 10, 2016", "JUN 27, 2016", "JUN 7, 2016", "JUN 1, 2016", "MAY 31, 2016", "MAY 20, 2016", "MAY 16, 2016", "MAY 9, 2016", "MAY 5, 2016", "JUN 9, 2016", "APR 28, 2016", "APR 28, 2016", "APR 27, 2016", "APR 27, 2016", "APR 27, 2016", "APR 26, 2016", "APR 25, 2016", "APR 29, 2016", "APR 25, 2016", "APR 25, 2016", "APR 25, 2016", "APR 25, 2016", "APR 22, 2016", "APR 22, 2016", "APR 22, 2016", "APR 25, 2016", "APR 22, 2016", "APR 21, 2016", "APR 21, 2016", "APR 20, 2016", "APR 18, 2016", "APR 12, 2016", "APR 11, 2016", "APR 22, 2016", "APR 9, 2016", "APR 7, 2016", "APR 7, 2016", "APR 7, 2016", "MAR 31, 2016", "MAR 29, 2016", "MAR 28, 2016", "APR 11, 2016", "MAR 22, 2016", "MAR 22, 2016", "MAR 21, 2016", "MAR 15, 2016", "MAR 9, 2016", "MAR 7, 2016", "MAR 4, 2016", "MAR 24, 2016", "MAR 2, 2016", "MAR 2, 2016", "FEB 29, 2016", "FEB 26, 2016", "FEB 26, 2016", "FEB 25, 2016", "FEB 25, 2016", "MAR 3, 2016", "FEB 23, 2016", "FEB 10, 2016", "FEB 10, 2016", "FEB 9, 2016", "FEB 8, 2016", "FEB 8, 2016", "FEB 7, 2016", "FEB 23, 2016", "FEB 3, 2016", "JAN 28, 2016", "JAN 27, 2016", "JAN 20, 2016", "JAN 19, 2016", "JAN 18, 2016", "JAN 15, 2016", "FEB 3, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 15, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 13, 2016", "JAN 15, 2016", "JAN 12, 2016", "JAN 3, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "JAN 13, 2016", "DEC 21, 2015", "DEC 18, 2015", "DEC 17, 2015", "DEC 16, 2015", "DEC 10, 2015", "DEC 6, 2015", "DEC 5, 2015", "DEC 21, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 25, 2015", "NOV 24, 2015", "NOV 27, 2015", "NOV 23, 2015", "NOV 23, 2015", "NOV 22, 2015", "NOV 20, 2015", "NOV 20, 2015", "NOV 20, 2015", "NOV 19, 2015", "NOV 23, 2015", "NOV 18, 2015", "NOV 12, 2015", "NOV 6, 2015", "NOV 1, 2015", "OCT 30, 2015", "OCT 29, 2015", "OCT 27, 2015", "NOV 18, 2015", "OCT 20, 2015", "OCT 19, 2015", "OCT 16, 2015", "OCT 15, 2015", "OCT 15, 2015", "OCT 15, 2015", "OCT 15, 2015", "OCT 20, 2015", "OCT 13, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 2, 2015", "OCT 2, 2015", "OCT 1, 2015", "OCT 1, 2015", "OCT 14, 2015", "SEP 30, 2015", "SEP 28, 2015", "SEP 24, 2015", "SEP 22, 2015", "SEP 21, 2015", "SEP 15, 2015", "SEP 11, 2015", "SEP 30, 2015", "AUG 28, 2015", "AUG 27, 2015", "AUG 27, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 26, 2015", "AUG 25, 2015", "SEP 3, 2015", "AUG 21, 2015", "AUG 20, 2015", "AUG 20, 2015", "AUG 18, 2015", "AUG 17, 2015", "AUG 15, 2015", "AUG 7, 2015", "AUG 22, 2015", "AUG 4, 2015", "AUG 3, 2015", "AUG 3, 2015", "JUL 31, 2015", "JUL 30, 2015", "JUL 30, 2015", "JUL 28, 2015", "AUG 4, 2015", "JUL 24, 2015", "JUL 21, 2015", "JUL 20, 2015", "JUL 7, 2015", "JUL 2, 2015", "JUL 1, 2015", "JUN 30, 2015", "JUL 28, 2015", "JUN 26, 2015", "JUN 25, 2015", "JUN 24, 2015", "JUN 19, 2015", "JUN 19, 2015", "JUN 19, 2015", "JUN 18, 2015", "JUN 30, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 18, 2015", "JUN 16, 2015", "JUN 9, 2015", "JUN 7, 2015", "JUN 18, 2015", "MAY 28, 2015", "MAY 27, 2015", "MAY 27, 2015", "MAY 26, 2015", "MAY 24, 2015", "MAY 20, 2015", "MAY 20, 2015", "MAY 30, 2015", "MAY 12, 2015", "MAY 10, 2015", "MAY 8, 2015", "MAY 7, 2015", "MAY 6, 2015", "MAY 4, 2015", "MAY 4, 2015", "MAY 20, 2015", "MAY 2, 2015", "MAY 1, 2015", "MAY 1, 2015", "MAY 1, 2015", "MAY 1, 2015", "APR 30, 2015", "APR 30, 2015", "MAY 4, 2015", "APR 29, 2015", "APR 29, 2015", "APR 29, 2015", "APR 28, 2015", "APR 27, 2015", "APR 11, 2015", "APR 10, 2015", "APR 29, 2015", "APR 7, 2015", "APR 1, 2015", "APR 1, 2015", "MAR 30, 2015", "MAR 30, 2015", "MAR 27, 2015", "MAR 27, 2015", "APR 10, 2015", "MAR 27, 2015", "MAR 26, 2015", "MAR 24, 2015", "MAR 17, 2015", "MAR 16, 2015", "MAR 13, 2015", "MAR 8, 2015", "MAR 27, 2015", "MAR 1, 2015", "FEB 27, 2015", "FEB 26, 2015", "FEB 26, 2015", "FEB 26, 2015", "FEB 26, 2015", "FEB 26, 2015", "MAR 3, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 25, 2015", "FEB 24, 2015", "FEB 26, 2015", "FEB 23, 2015", "FEB 23, 2015", "FEB 20, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 19, 2015", "FEB 18, 2015", "FEB 24, 2015", "FEB 17, 2015", "FEB 17, 2015", "FEB 16, 2015", "FEB 16, 2015", "FEB 14, 2015", "FEB 13, 2015", "FEB 12, 2015", "FEB 18, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 11, 2015", "FEB 2, 2015", "FEB 1, 2015", "JAN 28, 2015", "FEB 12, 2015", "JAN 24, 2015", "JAN 22, 2015", "JAN 22, 2015", "JAN 21, 2015", "JAN 17, 2015", "JAN 14, 2015", "JAN 11, 2015", "JAN 27, 2015", "DEC 30, 2014", "DEC 29, 2014", "DEC 26, 2014", "DEC 16, 2014", "DEC 9, 2014", "DEC 8, 2014", "NOV 26, 2014", "JAN 9, 2015", "DEC 30, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 26, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 20, 2014", "NOV 14, 2014", "NOV 12, 2014", "NOV 24, 2014", "NOV 5, 2014", "OCT 26, 2014", "OCT 24, 2014", "OCT 24, 2014", "OCT 23, 2014", "OCT 23, 2014", "OCT 21, 2014", "NOV 5, 2014", "SEP 15, 2014", "SEP 5, 2014", "SEP 5, 2014", "SEP 3, 2014", "AUG 27, 2014", "AUG 26, 2014", "SEP 25, 2014", "AUG 7, 2014", "JUL 31, 2014", "JUL 31, 2014", "JUL 30, 2014", "JUL 24, 2014", "JUL 23, 2014", "JUL 23, 2014", "AUG 7, 2014", "JUL 18, 2014", "JUL 17, 2014", "JUL 16, 2014", "JUL 15, 2014", "JUL 14, 2014", "JUL 8, 2014", "JUL 3, 2014", "JUL 21, 2014", "MAY 29, 2014", "MAY 2, 2014", "APR 24, 2014", "APR 16, 2014", "APR 15, 2014", "MAR 27, 2014", "JUN 25, 2014", "MAR 26, 2014", "MAR 20, 2014", "FEB 28, 2014", "FEB 26, 2014", "FEB 21, 2014", "FEB 19, 2014", "FEB 19, 2014", "MAR 27, 2014", "JAN 23, 2014", "JAN 22, 2014", "JAN 15, 2014", "JAN 8, 2014", "JAN 8, 2014", "JAN 7, 2014", "JAN 3, 2014", "FEB 18, 2014", "DEC 5, 2013", "NOV 27, 2013", "NOV 22, 2013", "NOV 21, 2013", "NOV 20, 2013", "NOV 18, 2013", "NOV 18, 2013", "DEC 10, 2013", "OCT 25, 2013", "OCT 25, 2013", "OCT 25, 2013", "OCT 22, 2013", "OCT 21, 2013", "OCT 18, 2013", "OCT 16, 2013", "NOV 15, 2013", "SEP 30, 2013", "SEP 24, 2013", "SEP 20, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 19, 2013", "SEP 18, 2013", "OCT 8, 2013", "SEP 17, 2013", "SEP 11, 2013", "AUG 28, 2013", "JUL 26, 2013", "JUL 25, 2013", "JUL 8, 2013", "JUL 5, 2013", "SEP 17, 2013", "JUN 3, 2013", "APR 29, 2013", "APR 11, 2013", "APR 3, 2013", "APR 2, 2013", "MAR 21, 2013", "MAR 14, 2013", "JUN 3, 2013", "FEB 21, 2013", "FEB 20, 2013", "JAN 10, 2013", "DEC 11, 2012", "NOV 19, 2012", "NOV 6, 2012", "NOV 5, 2012", "FEB 22, 2013", "FEB 21, 2013", "FEB 20, 2013", "SEP 27, 2012", "SEP 6, 2012", "AUG 2, 2012", "AUG 1, 2012", "JUL 11, 2012", "OCT 26, 2012", "MAY 31, 2012", "APR 2, 2012", "MAR 14, 2012", "FEB 17, 2012", "FEB 15, 2012", "FEB 14, 2012", "FEB 8, 2012", "JUN 1, 2012", "DEC 22, 2011", "DEC 1, 2011", "NOV 29, 2011", "JUN 22, 2011", "JAN 12, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/biomarin-to-participate-in-goldman-sachs-global-healthcare-conference-webcast-at-2%3A10-pm", "https://www.nasdaq.com/articles/how-biotech-companies-are-valued-2020-06-08", "https://www.nasdaq.com/articles/biomarin-to-participate-in-jefferies-virtual-healthcare-conference-at-4%3A00-pm-et-2020-06", "https://www.nasdaq.com/articles/2-best-biotech-stocks-to-buy-right-now-2020-06-01", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-atvi-pypl-2020-05-07", "https://www.nasdaq.com/articles/biomarin-dinaqor-to-develop-gene-therapies-for-rare-genetic-cardiomyopathies-2020-05-03", "https://www.nasdaq.com/articles/biomarin-pharma-q1-20-earnings-conference-call-at-4%3A15-pm-et-2020-04-30", "https://www.nasdaq.com/articles/biomarin-blows-past-q1-estimates-projects-1st-year-of-profitability-in-2020-2020-04-30", "https://www.nasdaq.com/articles/biomarin-to-participate-in-goldman-sachs-global-healthcare-conference-webcast-at-2%3A10-pm", "https://www.nasdaq.com/articles/earnings-summary%3A-details-of-biomarin-pharmaceutical-inc.-q1-earnings-report-2020-04-29", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-q1-20-earnings-conference-call-at-4%3A15-pm-et-2020-04-29", "https://www.nasdaq.com/articles/look-under-the-hood%3A-qqxt-has-10-upside-2020-04-27", "https://www.nasdaq.com/articles/is-biomarin-pharmaceuticals-stock-a-buy-2020-04-08", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-bmrn-2020-04-07", "https://www.nasdaq.com/articles/30-top-stocks-and-funds-to-beat-the-covid-19-bear-market-2020-04-05", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-now-2020-04-02", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q1-2020-earnings-call-transcript-2020-04-30", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bristol-myers-squibb-and-bluebird-bio-are-getting-hammered", "https://www.nasdaq.com/articles/why-these-drug-stocks-soared-today-2020-03-13", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc.-stock-is-fading-today-2020-03-12", "https://www.nasdaq.com/articles/heres-why-emergent-biosolutions-biomarin-and-nuvasive-fell-on-monday-2020-03-10", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q4-2019-earnings-call-transcript-2020-02-27", "https://www.nasdaq.com/articles/biomarin-expects-to-be-profitable-in-fy20-revenue-to-rise-14-20-2020-02-26", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc.-q4-adjusted-earnings-of-%24-per-share-2020-02-26", "https://www.nasdaq.com/articles/implied-vug-analyst-target-price%3A-%24203-2020-03-26", "https://www.nasdaq.com/articles/first-week-of-october-16th-options-trading-for-biomarin-pharmaceutical-bmrn-2020-02-26", "https://www.nasdaq.com/articles/biomarins-novel-treatment-promises-to-disrupt-competitors-2020-02-26", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-gluu-bmrn-seas-2020-02-21", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-algn-bmrn-2020-02-21", "https://www.nasdaq.com/articles/fda-gives-biomarin-pharmaceuticals-hemophilia-gene-therapy-priority-review-2020-02-21", "https://www.nasdaq.com/articles/why-invitaes-q4-results-failed-to-wow-investors-2020-02-20", "https://www.nasdaq.com/articles/codexis-is-chasing-a-blockbuster-opportunity.-can-it-compete-with-gene-therapies-2020-01", "https://www.nasdaq.com/articles/biomarin-pharma-q4-19-earnings-conference-call-at-4%3A30-pm-et-2020-02-26", "https://www.nasdaq.com/articles/add-up-the-parts%3A-fbt-could-be-worth-%24182-2020-01-21", "https://www.nasdaq.com/articles/3-top-biotech-picks-for-2020-2020-01-20", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-docu-bmrn-bhvn-2020-01-17", "https://www.nasdaq.com/articles/biomarin-considers-%243-million-price-tag-for-new-hemophilia-gene-therapy-2020-01-16", "https://www.nasdaq.com/articles/3-healthcare-stocks-that-are-coming-back-to-life-2020-01-15", "https://www.nasdaq.com/articles/biomarin-pharma-to-present-at-j.p.-morgan-conference-webcast-at-10%3A30-am-et-2020-01-13", "https://www.nasdaq.com/articles/these-3-biotech-stocks-could-be-top-stocks-in-2020-2020-01-11", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-for-march-20th-2020-01-22", "https://www.nasdaq.com/articles/3-best-stocks-for-2020%3A-the-race-is-on-2020-01-06", "https://www.nasdaq.com/articles/analysts-see-11-upside-for-the-holdings-of-bbh-2019-12-20", "https://www.nasdaq.com/articles/axsm-again-proves-it-is-awesome-mirm-leaps-to-%2422-wve-doesnt-go-the-distance-2019-12-16", "https://www.nasdaq.com/articles/biomarin%3A-vosoritide-phase-3-study-shows-positive-results-quick-facts-2019-12-16", "https://www.nasdaq.com/articles/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-2019-12-14", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-0", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05-1", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-fgen-bmrn-estc-2020-01-09", "https://www.nasdaq.com/articles/heres-why-biomarin-pharmaceutical-leapt-10.2-in-november-2019-12-04", "https://www.nasdaq.com/articles/better-buy%3A-editas-medicine-or-sangamo-therapeutics-2019-11-26", "https://www.nasdaq.com/articles/these-3-strong-buy-healthcare-stocks-have-40-upside-or-more-says-cowen-2019-11-20", "https://www.nasdaq.com/articles/implied-qqxt-analyst-target-price%3A-%2462-2019-11-18", "https://www.nasdaq.com/articles/2-beaten-down-biotech-stocks-that-could-make-you-rich-2019-11-11", "https://www.nasdaq.com/articles/3-reasons-biomarin-pharmaceutical-stock-is-a-buy-right-now-2019-10-24", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q3-2019-earnings-call-transcript-2019-10-24", "https://www.nasdaq.com/articles/why-has-alnylams-stock-gained-25-in-the-last-two-weeks-2019-12-05", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-q3-19-earnings-conference-call-at-4%3A30-pm-et-2019-10-23", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-nflx-isrg-2019-10-18", "https://www.nasdaq.com/articles/2-high-growth-stocks-to-buy-right-now-2019-10-17", "https://www.nasdaq.com/articles/december-20th-options-now-available-for-biomarin-pharmaceutical-bmrn-2019-10-01", "https://www.nasdaq.com/articles/november-15th-options-now-available-for-biomarin-pharmaceutical-bmrn-2019-09-19", "https://www.nasdaq.com/articles/biomarin-pharma-to-present-at-morgan-stanley-conference-webcast-at-8%3A35-am-et-2019-09-10", "https://www.nasdaq.com/articles/notable-friday-option-activity%3A-biib-bmrn-el-2019-08-16", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc.-q3-adjusted-earnings-beat-estimates-2019-10-23", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q2-2019-earnings-call-transcript-2019-08-02", "https://www.nasdaq.com/articles/shake-up-in-big-weed-2019-07-12", "https://www.nasdaq.com/articles/analysts-predict-29-upside-for-the-holdings-of-ibb-2019-07-11", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-july-2019-07-09", "https://www.nasdaq.com/articles/heres-why-sangamo-therapeutics-is-surging-today-2019-07-08", "https://www.nasdaq.com/articles/math-shows-eqal-can-go-%2437-2019-06-10", "https://www.nasdaq.com/articles/3-top-growth-stocks-buy-june-2019-06-09", "https://www.nasdaq.com/articles/biomarins-roller-coaster-continues-2019-08-06", "https://www.nasdaq.com/articles/%242.1-million-price-tag-novartis-zolgensma-ridiculous-2019-05-31", "https://www.nasdaq.com/articles/how-biomarin-may-revolutionize-hemophilia-treatment-market-2019-05-28", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2019-05-28", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-28-2019%3A-kzrtevatrxcbmrn-2019-05-28", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-bhvn-bmrn-ash-2019-05-28", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-28-2019%3A-tevatrxcbmrn-2019-05-28", "https://www.nasdaq.com/articles/health-care-sector-update-for-05-28-2019%3A-trxc-qtnt-bmrn-jnj-pfe-abt-mrk-amgn-2019-05-28", "https://www.nasdaq.com/articles/september-20th-options-now-available-biomarin-pharmaceutical-bmrn-2019-06-03", "https://www.nasdaq.com/articles/3-big-biotech-stocks-warren-buffett-might-2019-05-26", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-bpmc-bmrn-pgr-2019-05-15", "https://www.nasdaq.com/articles/analysts-expect-qqew-will-reach-72-2019-05-09", "https://www.nasdaq.com/articles/biomarin-isnt-gene-therapy-company-2019-05-01", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q1-2019-earnings-call-transcript-2019-04-26", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc.-q1-adjusted-earnings-%24-share-2019-04-25", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-q1-19-earnings-conference-call-4%3A30-pm-et-2019-04-25", "https://www.nasdaq.com/articles/biomarin-reports-positive-data-valoctocogene-roxaparvovec-study-2019-05-28", "https://www.nasdaq.com/articles/3-big-biotech-stocks-warren-buffett-might-2019-05-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-ea-symc-2019-04-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-ea-symc-2019-04-08-0", "https://www.nasdaq.com/articles/does-sangamo-have-best-gene-therapy-program-now-2019-04-03", "https://www.nasdaq.com/articles/sp-fights-past-growth-concerns-reclaim-2800-2019-03-27", "https://www.nasdaq.com/articles/3-stocks-buy-ahead-next-market-crash-2019-03-25", "https://www.nasdaq.com/articles/why-is-biomarin-bmrn-down-0.9-since-last-earnings-report-2019-03-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-qcom-2019-04-17", "https://www.nasdaq.com/articles/boeing-keeps-dow-joining-rally-2019-03-13", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-march-7th-2019-03-07", "https://www.nasdaq.com/articles/how-pieces-add-qqew-targets-69-2019-03-07", "https://www.nasdaq.com/articles/sarepta-srpt-q4-earnings-lag-estimates-exondys-51-sales-up-2019-02-28", "https://www.nasdaq.com/articles/2-more-gene-therapy-stocks-big-pharmas-buyout-radar-2019-02-26", "https://www.nasdaq.com/articles/biomarin-revenue-slips-big-picture-looks-dandy-2019-02-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-bmrn-2019-02-25", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-march-18th-2019-03-18", "https://www.nasdaq.com/articles/roche-steps-gene-therapy-43-bln-spark-bet-2019-02-25", "https://www.nasdaq.com/articles/roche-bets-43-bln-spark-gene-therapy-move-2019-02-25", "https://www.nasdaq.com/articles/roche-buy-gene-therapy-specialist-spark-43-bln-deal-2019-02-25", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q4-2018-earnings-conference-call-transcript-2019-02-22", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-earnings-sales-miss-shares-decline-2019-02-22", "https://www.nasdaq.com/articles/earnings-reaction-history-biomarin-pharma-375-follow-through-indicator-18-sensitive-2019", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-21-2019-intu-khc-bidu-ed-hpe-sbac-pba-bmrn-keys-dxcm", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-755446-2691-points-2019-02-25", "https://www.nasdaq.com/articles/catalyst-pharma-sees-net-price-drug-once-free-topping-300000-2019-02-11", "https://www.nasdaq.com/articles/sangamos-gene-editing-approach-bust-2019-02-09", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-2019-02-07", "https://www.nasdaq.com/articles/3-gene-therapy-stocks-huge-catalysts-2019-2019-02-03", "https://www.nasdaq.com/articles/notable-thursday-option-activity-iac-enva-bmrn-2019-01-31", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-stock-bargain-2019-01-14", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-stock-starting-shine-again-2019-01-11", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-reports-next-week%3A-wall-street-expects-earnings-growth-2019-1", "https://www.nasdaq.com/articles/bmrn-makes-bullish-cross-above-critical-moving-average-2019-01-10", "https://www.nasdaq.com/articles/biomarin-present-jp-morgan-conference-webcast-1130-am-et-2019-01-07", "https://www.nasdaq.com/articles/analysts-anticipate-21-upside-ntsx-2019-01-03", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-thrm-wtw-bmrn-2019-01-03", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-now-oversold-bmrn-2018-12-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-wday-ntes-2018-12-21", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-gco-bmrn-nbix-2018-12-12", "https://www.nasdaq.com/articles/5-biotech-stocks-could-face-ma-next-2019-01-10", "https://www.nasdaq.com/articles/why-catalyst-pharmaceuticals-stock-sinking-today-2018-11-29", "https://www.nasdaq.com/articles/sarepta-stock-more-than-doubles-this-year-so-far%3A-heres-why-2018-11-23", "https://www.nasdaq.com/articles/market-votes-clarity-2018-11-07", "https://www.nasdaq.com/articles/analysts-anticipate-ntsx-hit-28-2018-11-02", "https://www.nasdaq.com/articles/biomarin-keeps-pace-its-2-billion-goal-2018-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10262018-omclbmrnrdysgyp-2018-10-26", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-q3-2018-earnings-conference-call-transcript-2018-10-26", "https://www.nasdaq.com/articles/5-top-drugbiotech-merger-acquisition-targets-2019-2018-12-10", "https://www.nasdaq.com/articles/biomarin-bmrn-q3-earnings-revenues-surpass-estimates-2018-10-26", "https://www.nasdaq.com/articles/sarepta-srpt-q3-earnings-sales-miss-exondys-51-sales-up-2018-10-25", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-25-2018-amzn-googl-intc-gild-syk-ftv-dfs-dlr-rsg-cern", "https://www.nasdaq.com/articles/dow-sp-now-red-2018-2018-10-25", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-q3-earnings-preview%3A-what-to-watch-ahead-of-the-release-2018", "https://www.nasdaq.com/articles/nasdaq-ends-losing-skid-tech-rebounds-2018-10-10", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-778845-down-9106-points-2018-10-05", "https://www.nasdaq.com/articles/health-care-sector-update-10262018-bmrnrdysgyp-2018-10-26", "https://www.nasdaq.com/articles/dow-all-alone-record-territory-2018-10-03", "https://www.nasdaq.com/articles/sum-pieces-qqew-could-be-worth-72-2018-10-02", "https://www.nasdaq.com/articles/first-week-november-16th-options-trading-biomarin-pharmaceutical-bmrn-2018-09-26", "https://www.nasdaq.com/articles/stocks-stall-ahead-hike-2018-09-26", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-bmrn-adp-amcx-2018-09-21", "https://www.nasdaq.com/articles/sangamos-zinc-fingers-fail-again-time-walk-away-2018-09-06", "https://www.nasdaq.com/articles/sluggish-start-september-2018-09-05", "https://www.nasdaq.com/articles/3-biotech-stocks-virtual-monopolies-2018-10-03", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-782101-468-points-2018-08-20", "https://www.nasdaq.com/articles/3-tough-luck-tumbles-healthcare-are-they-buys-2018-08-17", "https://www.nasdaq.com/articles/spark-therapeutics-bad-news-buy-2018-08-17", "https://www.nasdaq.com/articles/notable-thursday-option-activity-mo-bmrn-de-2018-08-16", "https://www.nasdaq.com/articles/whats-next-spark-therapeutics-2018-08-15", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-catches-eye%3A-stock-jumps-7.9-2018-08-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-xray-bmrn-2018-08-07", "https://www.nasdaq.com/articles/analysts-predict-10-gains-ahead-holdings-dwpp-2018-08-31", "https://www.nasdaq.com/articles/biomarin-bmrn-q2-earnings-miss-estimates-revenues-beat-2018-08-03", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-2-2018-eog-atvi-aig-ed-cern-msi-flt-anet-pba-cbs-bmrn", "https://www.nasdaq.com/articles/drug-stock-q2-earnings-releases-on-aug-2%3A-zts-regn-more-2018-08-01", "https://www.nasdaq.com/articles/biomarin-bmrn-to-report-q2-earnings%3A-whats-in-the-cards-2018-07-30", "https://www.nasdaq.com/articles/look-under-hood-qqew-has-12-upside-2018-07-30", "https://www.nasdaq.com/articles/pfizers-hemophilia-b-gene-therapy-candidate-enters-phase-iii-2018-07-17", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-sets-its-sights-2-billion-2018-08-07", "https://www.nasdaq.com/articles/sareptas-dmd-portfolio-solid-sole-drug-dependence-concerns-2018-07-05", "https://www.nasdaq.com/articles/math-shows-qqew-can-go-70-2018-06-28", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-catches-eye%3A-stock-jumps-8.5-2018-06-18", "https://www.nasdaq.com/articles/biomarin-begins-pediatric-study-on-achondroplasia-candidate-2018-06-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-adbe-bmrn-2018-06-15", "https://www.nasdaq.com/articles/3-biotech-stocks-up-in-the-past-month-on-industry-turnaround-2018-06-15", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-774638-down-1466-points-2018-06-15", "https://www.nasdaq.com/articles/18-stocks-that-could-be-takeover-targets-2018-07-10", "https://www.nasdaq.com/articles/sareptas-dmd-portfolio-solid-sole-drug-dependence-concerns-2018-07-05", "https://www.nasdaq.com/articles/3-biotech-stocks-up-in-the-past-month-on-industry-turnaround-2018-06-05", "https://www.nasdaq.com/articles/10-hot-stock-picks-summer-rally-2018-06-01", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31-0", "https://www.nasdaq.com/articles/5-biotech-stocks-boost-your-portfolios-health-year-2018-05-31", "https://www.nasdaq.com/articles/catalysts-fridapse-gets-priority-review-by-fda-shares-up-2018-05-31", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-bmrn-athn-ba-2018-06-15", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gild-epclusas-china-approval-bmrn-palynziqs-fda-nod-2018-05-30", "https://www.nasdaq.com/articles/heres-why-sarepta-is-up-more-than-60-so-far-this-year-2018-05-29", "https://www.nasdaq.com/articles/which-best-hemophilia-stock-buy-now-2018-05-26", "https://www.nasdaq.com/articles/rare-disease-biotech-scores-important-win-2018-05-26", "https://www.nasdaq.com/articles/biomarins-palynziq-gets-fda-approval-for-phenylketonuria-2018-05-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-rost-bmrn-2018-05-25", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-743385-942-points-2018-05-25", "https://www.nasdaq.com/articles/allergan-recalls-taytulla-oral-contraceptives-stock-down-2018-05-30", "https://www.nasdaq.com/articles/big-decision-fast-approaching-rare-disease-drugmaker-2018-05-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-mu-2018-05-22", "https://www.nasdaq.com/articles/health-care-sector-update-05222018-vbivctmxrdybmrn-2018-05-22", "https://www.nasdaq.com/articles/biomarin-begins-mid-stage-study-on-gene-therapy-candidate-2018-05-16", "https://www.nasdaq.com/articles/merck-kgaa-mkgaf-q1-earnings-and-revenues-decline-y-y-2018-05-15", "https://www.nasdaq.com/articles/bmrn-makes-bullish-cross-above-critical-moving-average-2018-05-07", "https://www.nasdaq.com/articles/biomarin-cruises-while-it-waits-seventh-approval-2018-04-27", "https://www.nasdaq.com/articles/health-care-sector-update-05252018-bmrnrmtialxnevfm-2018-05-25", "https://www.nasdaq.com/articles/implied-iwf-analyst-target-price-157-2018-04-26", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biomarin-bmrn-in-q1-earnings-2018-04-24", "https://www.nasdaq.com/articles/catalyst-enrolls-first-patient-in-phase-iii-firdapse-study-2018-04-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-agios-pharmaceuticals-biomarin-pharmaceutical-vertex", "https://www.nasdaq.com/articles/pfizer-starts-phase-ib-for-duchenne-muscular-dystrophy-drug-2018-04-13", "https://www.nasdaq.com/articles/gene-therapy-in-limelight-on-novartis-deal%3A-3-stocks-in-focus-2018-04-13", "https://www.nasdaq.com/articles/pharma-ma-active-week-4-potential-buyout-targets-2018-04-13", "https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings-lower-than-expected-sales-beat-2018-04-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-695034-3523-points-2018-04-09", "https://www.nasdaq.com/articles/catalyst-cprx-up-on-new-drug-application-for-firdapse-2018-04-05", "https://www.nasdaq.com/articles/biomarins-maa-for-phenylketonuria-candidate-gains-eu-nod-2018-03-29", "https://www.nasdaq.com/articles/5-biotech-stocks-amazing-pipelines-2018-03-27", "https://www.nasdaq.com/articles/dwpps-underlying-holdings-could-mean-15-gain-potential-2018-03-26", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-down-3.1-since-earnings-report%3A-can-it-rebound-2018-03-26", "https://www.nasdaq.com/articles/biomarin-turns-profit-adjusted-basis-2018-02-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-trading-volume-joins-top-ten-ranking-year-nasdaq-composite-10", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-loss-wider-than-expected-sales-beat-2018-02-23", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-733739-12730-points-2018-02-23", "https://www.nasdaq.com/articles/earnings-reaction-history-biomarin-pharmaceutical-333-follow-through-indicator-21", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-22-2018-intu-hpq-hpe-eix-es-meli-bmrn-pba-lnt-ndsn", "https://www.nasdaq.com/articles/what-to-expect-from-biomarin-bmrn-this-earnings-season-2018-02-20", "https://www.nasdaq.com/articles/catalyst-gets-positive-fda-advise-on-firdapse-nda-refiling-2018-02-14", "https://www.nasdaq.com/articles/vertex-vrtx-other-drug-stocks-fda-catalysts-february-2018-01-31", "https://www.nasdaq.com/articles/first-week-october-19th-options-trading-biomarin-pharmaceutical-bmrn-2018-02-23", "https://www.nasdaq.com/articles/heres-why-sangamo-therapeutics-inc-stock-soared-438-2017-2018-01-09", "https://www.nasdaq.com/articles/why-gene-therapy-pioneer-crashed-298-december-2018-01-06", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-biomarin-pharmaceutical-bmrn-2018-01-05", "https://www.nasdaq.com/articles/what-drives-catalyst-pharmaceuticals-above-250-this-year-2017-12-28", "https://www.nasdaq.com/articles/biotech-stock-roundup-biib-celg-hit-pipeline-news-acquisition-deals-ignyta-sucampo-2017-12", "https://www.nasdaq.com/articles/biomarins-bmrn-pegvaliase-review-period-extended-by-fda-2017-12-26", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-xt-ctsh-meli-bmrn-2017-12-22", "https://www.nasdaq.com/articles/fbts-holdings-imply-17-gain-potential-2018-01-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-orly-shpg-2017-12-19", "https://www.nasdaq.com/articles/new-gene-therapies-could-change-hemophilia-forever-2017-12-19", "https://www.nasdaq.com/articles/fda-just-blessed-hemophilia-trial-biotech-2017-12-15", "https://www.nasdaq.com/articles/alnylam-gets-some-welcome-news-2017-12-15", "https://www.nasdaq.com/articles/5-biotech-buyout-candidates-2018-2017-12-13", "https://www.nasdaq.com/articles/spark-therapeutics-stock-plunges-on-hemophilia-therapy-data-2017-12-12", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-jumps%3A-stock-rises-7.5-2017-12-12", "https://www.nasdaq.com/articles/biomarins-bmrn-gene-therapy-enters-first-phase-iii-study-2017-12-20", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-stock-surging-today-2017-12-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-orly-bmrn-2017-12-11", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-2724-points-week-rising-4th-straight-day-2017-12-11", "https://www.nasdaq.com/articles/heres-why-sarepta-stock-is-up-more-than-70-in-6-months-2017-12-05", "https://www.nasdaq.com/articles/10-blockbuster-drugs-future-big-pharma-stocks-2017-11-30", "https://www.nasdaq.com/articles/catalyst-cprx-reports-positive-phase-iii-data-on-firdapse-2017-11-28", "https://www.nasdaq.com/articles/catalyst-initiates-phase-ii-study-for-pipeline-drug-firdapse-2017-11-22", "https://www.nasdaq.com/articles/heres-why-spark-therapeutics-inc-getting-hammered-today-2017-12-11", "https://www.nasdaq.com/articles/ultragenyxs-rhgus-gets-fda-nod-for-rare-genetic-disease-2017-11-17", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-now-oversold-bmrn-2017-11-14", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-target-its-15-revenue-growth-goal-2017-11-01", "https://www.nasdaq.com/articles/if-celgene-buys-biotech-investors-should-win-big-time-2017-10-31", "https://www.nasdaq.com/articles/biomarin-bmrn-q3-loss-narrows-profit-guidance-raised-2017-10-27", "https://www.nasdaq.com/articles/sarepta-srpt-q3-loss-narrows-exondys-51-sales-view-raised-2017-10-26", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-etsy-azo-bmrn-2017-10-26", "https://www.nasdaq.com/articles/analysts-anticipate-21-upside-holdings-bbh-2017-11-20", "https://www.nasdaq.com/articles/ultragenyxs-rhgus-gets-fda-nod-for-rare-genetic-disease-2017-11-17", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-now-oversold-bmrn-2017-11-14", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-662422-2017-10", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-2017-10-18", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-bmrn-salt-abt-2017-10-18", "https://www.nasdaq.com/articles/how-sparks-gene-therapy-win-could-also-be-boon-these-biotechs-2017-10-13", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-december-15th-2017-10-02", "https://www.nasdaq.com/articles/whats-in-store-for-biomarin-bmrn-this-earnings-season-2017-10-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-bmrn-2017-09-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-first-cancer-biosimilar-halo-deals-raised-outlook-2017-09-20", "https://www.nasdaq.com/articles/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-2017-09-18", "https://www.nasdaq.com/articles/biomarin-says-fda-not-planning-an-adcom-for-pegvaliase-bla-2017-09-18", "https://www.nasdaq.com/articles/math-shows-fbt-can-go-140-2017-09-15", "https://www.nasdaq.com/articles/biomarin-bmrn-up-2.5-since-earnings-report%3A-can-it-continue-2017-09-07", "https://www.nasdaq.com/articles/biomarin-presents-interim-data-on-bmn-250-from-phase-i-ii-2017-09-07", "https://www.nasdaq.com/articles/heres-why-sarepta-stock-is-up-more-than-60-so-far-in-2017-2017-09-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-bmrn-2017-09-21", "https://www.nasdaq.com/articles/biomarin-bmrn-in-focus%3A-stock-moves-5.6-higher-2017-08-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-car-t-focus-gilead-kite-deal-incyte-baricitinib-update-2017-08-31", "https://www.nasdaq.com/articles/biomarins-pegvaliase-bla-granted-priority-review-by-the-fda-2017-08-30", "https://www.nasdaq.com/articles/these-3-stocks-look-expensive-are-actually-cheap-2017-08-29", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-twilio-inc-twlo-biomarin-pharmaceutical-inc.-bmrn-and", "https://www.nasdaq.com/articles/sareptas-golodirsen-positive-in-dmd-study-shares-soar-2017-09-07", "https://www.nasdaq.com/articles/why-gilead-sciences-might-not-make-oncology-acquisition-2017-08-15", "https://www.nasdaq.com/articles/analysts-forecast-10-gains-ahead-vxf-2017-08-14", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-got-it-done-second-quarter-2017-08-04", "https://www.nasdaq.com/articles/biomarin-bmrn-q2-loss-narrows-sales-surpass-estimates-2017-08-03", "https://www.nasdaq.com/articles/is-zoetis-zts-poised-for-a-beat-this-earnings-season-2017-08-01", "https://www.nasdaq.com/articles/can-horizon-pharma-hznp-spring-a-surprise-in-q2-earnings-2017-07-31", "https://www.nasdaq.com/articles/will-teladoc-tdoc-pull-off-a-surprise-in-q2-earnings-2017-07-31", "https://www.nasdaq.com/articles/relative-strength-alert-biomarin-pharmaceutical-2017-08-21", "https://www.nasdaq.com/articles/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-2017-07-27", "https://www.nasdaq.com/articles/sarepta-srpt-q2-loss-narrows-ups-exondys-51-sales-view-2017-07-20", "https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-stock-surged-24-today-heres-why-2017-07-20", "https://www.nasdaq.com/articles/sarepta-biomarin-settle-patent-litigation-on-exon-skipping-2017-07-19", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-631443-196-points-2017-07-17", "https://www.nasdaq.com/articles/wall-streets-5-hottest-biotech-stocks-right-now-2017-07-17", "https://www.nasdaq.com/articles/math-shows-bbh-can-go-140-2017-07-12", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-biomarin-bmrn-2017-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-cara-plunges-study-data-regulatory-updates-more-2017-07-05", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-shouldnt-buy-vertex-pharmaceuticals-2017-07-03", "https://www.nasdaq.com/articles/biomarin-files-bla-for-phenylketonuria-candidate-pegvaliase-2017-07-03", "https://www.nasdaq.com/articles/3-pivotal-drug-trials-watch-explosive-potential-2017-06-29", "https://www.nasdaq.com/articles/why-is-catalyst-pharmaceuticals-stock-up-160-this-year-2017-06-28", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-august-18th-2017-06-23", "https://www.nasdaq.com/articles/biomarin-bmrn-in-focus%3A-stock-moves-7-higher-2017-06-22", "https://www.nasdaq.com/articles/shire-completes-nda-filing-for-hemophilia-drug-with-fda-2017-07-07", "https://www.nasdaq.com/articles/sum-pieces-bbh-could-be-worth-138-2017-06-06", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-approved-by-european-commission-2017-06-02", "https://www.nasdaq.com/articles/health-care-sector-update-06012017-bmrn-2017-06-01", "https://www.nasdaq.com/articles/ultragenyx-receives-priority-review-for-rhgus-from-fda-2017-05-24", "https://www.nasdaq.com/articles/why-sangamo-therapeutics-inc-jumped-higher-today-2017-05-12", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-breaks-below-200-day-moving-average-notable-bmrn-2017-05-10", "https://www.nasdaq.com/articles/7-reasons-why-prescription-drug-prices-are-extremely-expensive-2017-06-09", "https://www.nasdaq.com/articles/biomarin-bmrn-down-8-since-earnings-report%3A-can-it-rebound-2017-06-08", "https://www.nasdaq.com/articles/sum-pieces-bbh-could-be-worth-138-2017-06-06", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-approved-by-european-commission-2017-06-02", "https://www.nasdaq.com/articles/after-hours-earnings-report-may-4-2017-atvi-mnst-ed-cbs-bmrn-msi-mtd-mro-pba-meli-anet-y", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-gilead-celgene-q1-earnings-sunesis-down-vosaroxin-update-2017", "https://www.nasdaq.com/articles/what-lies-ahead-for-stericycle-srcl-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-biomarin-report-q1-kite-down-patient-death-2017-05-10", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-moves-toward-profitability-2017-05-09", "https://www.nasdaq.com/articles/biomarin-bmrn-posts-earnings-in-q1-sales-top-stock-up-2017-05-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-gains-strong-q1-nash-data-gilead-drug-2017-04-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-bmrn-2017-04-24", "https://www.nasdaq.com/articles/notable-monday-option-activity-aa-vlo-bmrn-2017-04-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-oncomed-2017-04-19", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q1-earnings%3A-whats-in-store-2017-05-01", "https://www.nasdaq.com/articles/6-fda-events-watch-out-may-2017-2017-05-01", "https://www.nasdaq.com/articles/3-stocks-wed-buy-and-hold-next-20-years-2017-04-06", "https://www.nasdaq.com/articles/implied-iyh-analyst-target-price-171-2017-04-03", "https://www.nasdaq.com/articles/4-fda-decisions-watch-out-apr-2017-2017-04-03", "https://www.nasdaq.com/articles/4-drug-stocks-big-news-coming-april-2017-04-02", "https://www.nasdaq.com/articles/why-is-biomarin-bmrn-down-2.2-since-the-last-earnings-report-2017-03-28", "https://www.nasdaq.com/articles/catalyst-pharma-cprx-focused-on-u.s.-approval-for-firdapse-2017-03-23", "https://www.nasdaq.com/articles/5-drug-stocks-could-be-big-winners-earnings-season-2017-04-17", "https://www.nasdaq.com/articles/commit-purchase-biomarin-pharmaceutical-70-earn-81-using-options-2017-03-15", "https://www.nasdaq.com/articles/repros-rprx-q4-earnings%3A-whats-in-store-for-the-stock-2017-03-07", "https://www.nasdaq.com/articles/catalyst-pharma-cprx%3A-whats-in-store-in-q4-earnings-2017-03-07", "https://www.nasdaq.com/articles/inovio-ino%3A-whats-in-the-cards-this-earnings-season-2017-03-06", "https://www.nasdaq.com/articles/biodelivery-bdsi%3A-whats-in-store-this-earnings-season-2017-03-06", "https://www.nasdaq.com/articles/whats-in-store-for-merck-kgaa-mkgaf-in-q4-earnings-2017-03-06", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-q4-earnings%3A-whats-in-store-2017-03-06", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-2017-03-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-kite-soars-car-t-data-exel-immuno-oncology-deals-2017-03-01", "https://www.nasdaq.com/articles/aerie-pharmaceuticals-aeri-q4-earnings%3A-what-to-expect-2017-03-01", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-586190-1659-points-2017-02-27", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-logs-combined-blockbuster-2017-02-25", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-breaks-below-200-day-moving-average-notable-bmrn-2017-02-24", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-loss-narrower-than-expected-sales-beat-2017-02-24", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-23-2017-bidu-hpe-intu-bmrn-pba-gps-meli-lnt-splk-jwn", "https://www.nasdaq.com/articles/analysts-expect-bbh-will-reach-134-2017-03-02", "https://www.nasdaq.com/articles/biotech-stock-roundup-alexion-reports-4q-results-celgene-ms-drug-looks-promising-2017-02", "https://www.nasdaq.com/articles/3-biotech-stocks-you-may-be-overlooking-2017-02-22", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-biomarin-pharmaceutical-inc-2017-02-20", "https://www.nasdaq.com/articles/biomarin-bmrn-q4-earnings%3A-will-it-post-a-beat-again-2017-02-17", "https://www.nasdaq.com/articles/can-wright-medical-wmgi-surprise-investors-in-q4-earnings-2017-02-14", "https://www.nasdaq.com/articles/labcorp-lh-q4-earnings%3A-whats-in-the-cards-for-the-stock-2017-02-14", "https://www.nasdaq.com/articles/whats-in-store-for-immunogen-imgn-this-earnings-season-2017-02-13", "https://www.nasdaq.com/articles/drug-stocks-q4-earnings-slated-for-feb-23%3A-bmrn-icpt-more-2017-02-22", "https://www.nasdaq.com/articles/perrigo-company-prgo-q4-earnings%3A-disappointment-in-store-2017-02-10", "https://www.nasdaq.com/articles/will-zoetis-zts-disappoint-estimates-this-earnings-season-2017-02-10", "https://www.nasdaq.com/articles/teva-teva-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-08", "https://www.nasdaq.com/articles/5-great-biotech-stocks-buy-now-2017-02-07", "https://www.nasdaq.com/articles/biomarins-hemophilia-candidate-included-in-prime-initiative-2017-02-02", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shares-cross-above-200-dma-2017-02-01", "https://www.nasdaq.com/articles/is-biomarin-bmrn-well-poised-for-growth-in-2017-2017-01-26", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2017-02-10", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-breaks-above-200-day-moving-average-bullish-bmrn-2017-01-09", "https://www.nasdaq.com/articles/top-stocks-buy-now-21st-century-cures-act-has-passed-2017-01-09", "https://www.nasdaq.com/articles/biotech-investing-3-bold-predictions-2017-2017-01-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-sucampo-pharmaceuticals-dr.-reddys-laboratories", "https://www.nasdaq.com/articles/3-overlooked-drug-stocks-watch-out-2017-2017-01-03", "https://www.nasdaq.com/articles/biomarin-bmrn-raised-to-buy%3A-should-you-add-the-stock-2016-12-29", "https://www.nasdaq.com/articles/3-precision-medicine-stocks-buy-january-2016-12-27", "https://www.nasdaq.com/articles/look-under-hood-pxmg-has-10-upside-2017-01-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-538068-down-567-points-2016-11-23", "https://www.nasdaq.com/articles/5-biotech-stocks-george-soros-buying-2016-11-22", "https://www.nasdaq.com/articles/analysts-anticipate-qld-will-reach-94-2016-11-21", "https://www.nasdaq.com/articles/merck-kgaas-mkgaf-q3-earnings-and-sales-increase-y-y-2016-11-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-jd-2016-11-15", "https://www.nasdaq.com/articles/why-biomarin-bmrn-could-be-positioned-for-a-surge-2016-11-15", "https://www.nasdaq.com/articles/3-growth-stocks-you-should-avoid-2017-2016-12-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-nflx-2016-11-29", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sold-6-million-shares-2016-11", "https://www.nasdaq.com/articles/why-these-biotechs-are-soaring-today-2016-11-09", "https://www.nasdaq.com/articles/bmrn-crosses-above-key-moving-average-level-2016-11-09", "https://www.nasdaq.com/articles/biomarins-stock-tumbled-october-it-now-buy-2016-11-08", "https://www.nasdaq.com/articles/weighing-week-ahead-it-finally-time-clarity-2016-11-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-symc-alxn-2016-11-04", "https://www.nasdaq.com/articles/stock-exchange-post-election-technical-analysis-useful-2016-11-11", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-ceo-jean-jacques-bienaime-sold-98-million-shares-2016-10", "https://www.nasdaq.com/articles/immunogen-imgn-reports-wider-than-expected-loss-2016-10-31", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-sales-losses-down-waiting-pipeline-2016-10-31", "https://www.nasdaq.com/articles/abbvie-abbv-q3-earnings-in-line-revenues-lag-estimates-2016-10-28", "https://www.nasdaq.com/articles/biomarin-bmrn-q3-loss-narrows-y-y-pipeline-in-focus-2016-10-28", "https://www.nasdaq.com/articles/united-therapeutics-uthr-beats-q3-earnings-sales-miss-2016-10-28", "https://www.nasdaq.com/articles/agenus-agen-reports-wider-than-expected-loss-in-q3-2016-10-28", "https://www.nasdaq.com/articles/novo-nordisk-nvo-tops-q3-earnings-revenues-up-y-y-2016-10-31", "https://www.nasdaq.com/articles/acorda-acor-reports-wider-q3-loss-revenues-down-y-y-2016-10-28", "https://www.nasdaq.com/articles/mckesson-mck-misses-on-q2-earnings-sales-cuts-view-2016-10-28", "https://www.nasdaq.com/articles/seattle-genetics-sgen-loss-narrower-than-expected-in-q3-2016-10-28", "https://www.nasdaq.com/articles/celgene-celg-beats-on-q3-earnings-raises-16-outlook-2016-10-27", "https://www.nasdaq.com/articles/glaxo-gsk-beats-q3-earnings-estimates-keeps-2016-view-2016-10-27", "https://www.nasdaq.com/articles/bristol-myers-bmy-beats-on-q3-earnings-ups-2016-view-2016-10-27", "https://www.nasdaq.com/articles/the-medicines-co.-mdco-q3-loss-narrower-than-expected-2016-10-27", "https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-incurs-narrower-y-y-loss-in-q3-2016-10-28", "https://www.nasdaq.com/articles/proqr-therapeutics-prqr-worth-a-look%3A-stock-up-9.8-2016-10-27", "https://www.nasdaq.com/articles/alexion-alxn-q3-earnings-lag-revenues-tops-lifts-view-2016-10-27", "https://www.nasdaq.com/articles/dr.-reddys-rdy-earnings-revenues-decline-y-y-in-q2-2016-10-26", "https://www.nasdaq.com/articles/express-scripts-esrx-q3-earnings-in-line-revenues-lag-2016-10-26", "https://www.nasdaq.com/articles/vertexs-vrtx-q3-loss-wider-than-expected-sales-miss-2016-10-26", "https://www.nasdaq.com/articles/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-2016-10-25", "https://www.nasdaq.com/articles/lilly-lly-misses-on-q3-earnings-sales-animal-health-hurts-2016-10-25", "https://www.nasdaq.com/articles/bayer-bayry-beats-on-q3-earnings-lifts-2016-guidance-2016-10-27", "https://www.nasdaq.com/articles/ligand-partner-melinta-therapeutics-submits-nda-for-baxdela-2016-10-25", "https://www.nasdaq.com/articles/bristol-myerss-bmy-opdivo-under-priority-review-by-fda-2016-10-24", "https://www.nasdaq.com/articles/merck-gets-fda-approval-for-investigational-drug-zinplava-2016-10-24", "https://www.nasdaq.com/articles/commit-buy-biomarin-pharmaceutical-65-earn-86-using-options-2016-10-21", "https://www.nasdaq.com/articles/alkermes-depression-candidate-positive-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/how-parts-add-qus-targets-69-2016-10-21", "https://www.nasdaq.com/articles/roche-rhhby-misses-q3-sales-estimates-2016-view-intact-2016-10-21", "https://www.nasdaq.com/articles/inovio-stock-down-on-fda-hold-on-vgx-3100-phase-iii-study-2016-10-25", "https://www.nasdaq.com/articles/eli-lilly-lartruvo-gets-fda-approval-for-soft-tissue-sarcoma-2016-10-20", "https://www.nasdaq.com/articles/astrazenecas-hyperkalemia-drug-nda-resubmission-accepted-2016-10-19", "https://www.nasdaq.com/articles/the-medicines-co.-reports-positive-phase-ii-data-on-pcsk9si-2016-10-19", "https://www.nasdaq.com/articles/3-top-stocks-your-roth-ira-2016-10-19", "https://www.nasdaq.com/articles/jj-jnj-outshines-in-q3-earnings-on-strong-pharma-sales-2016-10-18", "https://www.nasdaq.com/articles/teva-trisenox-wins-chmp-nod-for-expanded-use-in-leukemia-2016-10-18", "https://www.nasdaq.com/articles/alexion-graft-versus-host-disease-drug-wins-orphan-status-2016-10-20", "https://www.nasdaq.com/articles/allergans-belkyra-gets-swedish-approval-for-double-chin-2016-10-17", "https://www.nasdaq.com/articles/bristol-myers-wins-chmp-nod-for-opdivo-label-expansion-2016-10-17", "https://www.nasdaq.com/articles/precious-metal-outlook-2016-10-17", "https://www.nasdaq.com/articles/david-rolfe-comments-treehouse-foods-2016-10-17", "https://www.nasdaq.com/articles/biomarin-issues-encouraging-update-on-hemophilia-a-drug-2016-10-14", "https://www.nasdaq.com/articles/sunesis-submits-response-to-questions-on-leukemia-drug-2016-10-14", "https://www.nasdaq.com/articles/oncogenex-cancer-drug-fails-in-phase-iii-study-stock-down-2016-10-14", "https://www.nasdaq.com/articles/tetraphase-begins-phase-iii-dosing-of-antibiotic-candidate-2016-10-17", "https://www.nasdaq.com/articles/amag-issues-encouraging-updates-on-makena-feraheme-2016-10-13", "https://www.nasdaq.com/articles/supernus-supn-reports-encouraging-data-from-adhd-study-2016-10-13", "https://www.nasdaq.com/articles/bmrn-crosses-below-key-moving-average-level-2016-10-13", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-523902-down-777-points-2016-10-12", "https://www.nasdaq.com/articles/3-biotechs-most-likely-be-acquired-2016-10-11", "https://www.nasdaq.com/articles/catabasis-presents-data-from-dmd-study-on-edasalonexent-2016-10-11", "https://www.nasdaq.com/articles/alexion-presents-new-long-term-phase-iii-data-on-kanuma-2016-10-11", "https://www.nasdaq.com/articles/what-makes-vertex-pharmaceuticals-vrtx-a-strong-sell-2016-10-13", "https://www.nasdaq.com/articles/sarepta-therapeutics-still-risky-bet-2016-10-02", "https://www.nasdaq.com/articles/better-buy-biomarin-pharmaceuticals-inc-vs-sarepta-therapeutics-inc-2016-09-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-alxn-bmrn-2016-09-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-bbby-2016-09-22", "https://www.nasdaq.com/articles/does-sarepta-therapeutics-incs-fda-win-make-shares-buy-2016-09-20", "https://www.nasdaq.com/articles/sarepta-stock-nearly-doubles-on-fda-approval-for-dmd-drug-2016-09-20", "https://www.nasdaq.com/articles/2-biotech-stocks-turned-8000-over-250000-2016-09-12", "https://www.nasdaq.com/articles/new-strong-buy-stocks-october-6th-2016-10-06", "https://www.nasdaq.com/articles/biomarins-bmrn-brineura-review-period-extended-by-fda-2016-09-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-colucid-soars-migraine-data-dynavax-drug-fda-panel-meeting-cancelled", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-incy-2016-08-22", "https://www.nasdaq.com/articles/why-syngenta-valeant-pharmaceuticals-and-biomarin-pharmaceutical-jumped-today-2016-08-22", "https://www.nasdaq.com/articles/we-did-math-pth-can-go-54-2016-08-17", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-biomarin-pharmaceutical-bmrn-stock-2016-08-16", "https://www.nasdaq.com/articles/7-battered-biotech-stocks-buy-2016-08-14", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-pbe-incy-bmrn-regn-2016-09-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-earnings-focus-abbvie-takes-steps-block-humira-copycat-2016-08-11", "https://www.nasdaq.com/articles/solid-biomarin-pharmaceutical-inc-earnings-more-come-2016-08-10", "https://www.nasdaq.com/articles/health-care-sector-update-08092016-nvrohiiqbmrn-2016-08-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-mchp-2016-08-09", "https://www.nasdaq.com/articles/why-wayfair-inc-w-biomarin-pharmaceutical-inc.-bmrn-and-norwegian-cruise-line-holdings-ltd", "https://www.nasdaq.com/articles/health-care-sector-update-08092016-ipxlhiiqbmrn-2016-08-09", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-stock-rose-222-july-2016-08-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-regeneron-biomarin-abbvie-amgen-and-biogen-2016-08-12", "https://www.nasdaq.com/articles/merck-kgaa-mkgaf-q2-earnings-fall-guides-up-on-sales-2016-08-05", "https://www.nasdaq.com/articles/earnings-reaction-history-biomarin-pharmaceutical-500-follow-through-indicator-31", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-4-2016-khc-pcln-atvi-ed-lnkd-bmrn-mhk-flt-symc-msi-frt", "https://www.nasdaq.com/articles/5-drug-stocks-to-watch-for-earnings-on-aug-4%3A-bmrn-more-2016-08-03", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-biomarin-pharmaceutical-bmrn-this-earnings-season-2016-08-03", "https://www.nasdaq.com/articles/will-aveo-aveo-pull-a-surprise-this-earnings-season-2016-08-03", "https://www.nasdaq.com/articles/can-gw-pharmaceuticals-gwph-surprise-in-q3-earnings-2016-08-02", "https://www.nasdaq.com/articles/biomarin-bmrn-posts-narrower-q2-loss-sales-view-upped-2016-08-05", "https://www.nasdaq.com/articles/biomarin-bmrn-may-beat-in-q2-earnings%3A-stock-to-gain-2016-08-01", "https://www.nasdaq.com/articles/conatus-cnat-may-surprise-in-q2-earnings%3A-stock-to-gain-2016-08-01", "https://www.nasdaq.com/articles/sam-isaly-swaps-3-health-care-stocks-second-quarter-2016-07-30", "https://www.nasdaq.com/articles/pfizer-pfe-likely-to-beat-earnings-in-q2-again-2016-07-29", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-jumps%3A-stock-rises-6.6-2016-07-28", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-ions-tsro-bmrn-2016-07-27", "https://www.nasdaq.com/articles/merck-mrk-q2-earnings-will-stock-pull-surprise-2016-07-26", "https://www.nasdaq.com/articles/will-immunogen-imgn-disappoint-again-on-q4-earnings-2016-08-02", "https://www.nasdaq.com/articles/vertex-vrtx-report-q2-earnings-surprise-store-2016-07-25", "https://www.nasdaq.com/articles/amgen-amgn-may-beat-q2-earnings-will-stock-gain-2016-07-25", "https://www.nasdaq.com/articles/trade-day-breakout-could-send-bmrn-stock-25-higher-2016-07-25", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-with-biomarin-pharmaceutical-bmrn-2016-07-19", "https://www.nasdaq.com/articles/earnings-estimates-these-3-biotech-giants-should-be-heading-lower-heres-why-2016-07-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-ntes-2016-07-11", "https://www.nasdaq.com/articles/why-biomarins-shares-tumbled-11-june-2016-07-09", "https://www.nasdaq.com/articles/ariad-aria-report-q2-earnings-will-stock-surprise-2016-07-26", "https://www.nasdaq.com/articles/vertex-vrtx-report-q2-earnings-surprise-store-2016-07-25", "https://www.nasdaq.com/articles/bmrn-crosses-above-key-moving-average-level-2016-07-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-celg-bmrn-2016-07-07", "https://www.nasdaq.com/articles/pre-market-most-active-jul-7-2016-wwav-lyg-vrx-bac-bll-sanb-qqq-bmrn-xiv-roic-vod-fb-2016", "https://www.nasdaq.com/articles/why-avg-technologies-ezcorp-and-biomarin-pharmaceutical-jumped-today-2016-07-07", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc.-bmrn-western-digital-corp-wdc-and-whitewave-foods-co-wwav", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-bwld-cuda-bmrn-2016-07-07", "https://www.nasdaq.com/articles/catabasis-dmd-drug-in-phase-ii-open-label-extension-study-2016-07-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-lltc-bmrn-2016-06-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-aal-symc-2016-06-16", "https://www.nasdaq.com/articles/why-american-airlines-group-inc-aal-biomarin-pharmaceutical-inc.-bmrn-and-cavium-inc-cavm", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-anac-cacc-bmrn-2016-06-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-wfm-bmrn-2016-06-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-ishares-nasdaq-biotechnology-biogen-alexion-pharma", "https://www.nasdaq.com/articles/4-stocks-crushed-biotechnology-etf-ibb-week-2016-06-10", "https://www.nasdaq.com/articles/how-does-brexit-impact-healthcare-stocks-2016-06-27", "https://www.nasdaq.com/articles/sarepta-asked-to-provide-dystrophin-data-on-eteplirsen-2016-06-07", "https://www.nasdaq.com/articles/biomarin-withdraws-kyndrisa-marketing-application-in-eu-2016-06-01", "https://www.nasdaq.com/articles/10-biotech-stocks-with-symptoms-of-strong-growth-2016-05-31", "https://www.nasdaq.com/articles/merck-kgaas-q1-earnings-increase-y-y-offers-2016-view-2016-05-20", "https://www.nasdaq.com/articles/merck-kgaa-mkgaf-q1-earnings%3A-what-awaits-the-stock-2016-05-16", "https://www.nasdaq.com/articles/analysts-expect-19-upside-qqxt-2016-05-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-disca-2016-05-05", "https://www.nasdaq.com/articles/bbhs-holdings-imply-25-gain-potential-2016-06-09", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-big-today-2016-04-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-april-28-2016-amzn-gild-amgn-bidu-hig-rsg-expe-ess-bmrn-lnkd", "https://www.nasdaq.com/articles/drug-stocks-earnings-previews%3A-kerx-bxlt-bmrn-agen-imgn-2016-04-27", "https://www.nasdaq.com/articles/should-you-buy-biomarin-pharmaceutical-bmrn-ahead-of-earnings-2016-04-27", "https://www.nasdaq.com/articles/despite-pleas-fda-panel-shuns-drug-2016-04-27", "https://www.nasdaq.com/articles/alexion-alxn-q1-earnings%3A-whats-in-store-for-the-stock-2016-04-26", "https://www.nasdaq.com/articles/celgene-celg-q1-earnings%3A-whats-in-store-for-the-stock-2016-04-25", "https://www.nasdaq.com/articles/biomarin-bmrn-reports-narrower-than-expected-q1-loss-2016-04-29", "https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings%3A-stock-likely-to-beat-estimates-2016-04-25", "https://www.nasdaq.com/articles/amgen-amgn-may-beat-q1-earnings-will-stock-gain-2016-04-25", "https://www.nasdaq.com/articles/baxalta-bxlt-q1-earnings%3A-can-the-stock-pull-a-surprise-2016-04-25", "https://www.nasdaq.com/articles/5-biotech-stocks-to-bet-on-this-earnings-season-2016-04-25", "https://www.nasdaq.com/articles/bristol-myers-bmy-q1-earnings%3A-can-the-stock-surprise-2016-04-22", "https://www.nasdaq.com/articles/vertex-vrtx-report-q1-earnings-surprise-store-2016-04-22", "https://www.nasdaq.com/articles/abbvie-abbv-likely-beat-q1-earnings-stock-gain-2016-04-22", "https://www.nasdaq.com/articles/whats-in-store-for-keryx-kerx-this-earnings-season-2016-04-25", "https://www.nasdaq.com/articles/7-stocks-to-buy-before-summer-arrives-2016-04-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-mat-ctxs-2016-04-21", "https://www.nasdaq.com/articles/will-currency-competition-hurt-lillys-lly-q1-earnings-2016-04-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-chkp-bmrn-2016-04-20", "https://www.nasdaq.com/articles/will-ms-franchise-sales-boost-biogens-biib-1q-earnings-2016-04-18", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-bmrn-see-town-2016-04-12", "https://www.nasdaq.com/articles/3-ways-pfizer-can-improve-shareholder-value-without-allergan-2016-04-11", "https://www.nasdaq.com/articles/glaxo-gsk-q1-earnings%3A-whats-in-store-for-the-stock-2016-04-22", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-soared-44-higher-march-2016-04-09", "https://www.nasdaq.com/articles/3-drug-developers-pfizer-could-go-after-now-allergan-deal-officially-dead-2016-04-07", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-surged-20-in-wednesday-trading-2016-04-07", "https://www.nasdaq.com/articles/analysts-anticipate-mtum-will-reach-81-2016-04-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-endp-incy-2016-03-31", "https://www.nasdaq.com/articles/5-minute-guide-biomarin-pharmaceutical-stock-2016-03-29", "https://www.nasdaq.com/articles/biomarin-bmrn-bmn-270-gets-orphan-drug-status-in-eu-2016-03-28", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-you-can-buy-right-now-2016-04-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-bmrn-2016-03-22", "https://www.nasdaq.com/articles/biomarin-bmrn-down-on-phase-iii-data-on-pegvaliase-2016-03-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-endp-2016-03-21", "https://www.nasdaq.com/articles/sarepta-up-dmd-drug-eteplirsen-to-face-fda-panel-in-april-2016-03-15", "https://www.nasdaq.com/articles/sarepta-4-year-data-analysis-eteplirsen-treat-dmd-2016-03-09", "https://www.nasdaq.com/articles/what-awaits-merck-kgaa-mkgaf-this-earnings-season-2016-03-07", "https://www.nasdaq.com/articles/sanofi-genzyme-present-positive-pompe-disease-study-data-2016-03-04", "https://www.nasdaq.com/articles/gilead-biogens-patent-woes-amgen-scores-win-patent-litigation-2016-03-24", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-ratchets-profitability-talk-2016-03-02", "https://www.nasdaq.com/articles/health-care-sector-update-03022016-bmrn-evdy-xtlb-2016-03-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-endp-bmrn-2016-02-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-bidu-2016-02-26", "https://www.nasdaq.com/articles/biomarin-incurs-loss-in-q4-misses-estimates-gives-16-view-2016-02-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-ptct-plunges-rtf-fda-radius-shoots-amgen-data-2016-02-25", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-25-2016-bidu-eog-mnst-intu-gg-mhk-bmrn-sbac-dlr-adsk", "https://www.nasdaq.com/articles/biomarin-bmrn-presents-positive-data-on-cerliponase-alfa-2016-03-03", "https://www.nasdaq.com/articles/biomarin-bmrn-to-report-q4-earnings%3A-whats-in-store-2016-02-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-akam-2016-02-10", "https://www.nasdaq.com/articles/will-teva-teva-continue-its-earnings-streak-q4-2016-02-10", "https://www.nasdaq.com/articles/sarepta-hits-52-week-low-eteplirsen-review-period-extended-2016-02-09", "https://www.nasdaq.com/articles/vxf-lnkd-incy-bmrn-etf-outflow-alert-2016-02-08", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-down-today-2016-02-08", "https://www.nasdaq.com/articles/why-shares-sarepta-therapeutics-inc-collapsed-january-2016-02-07", "https://www.nasdaq.com/articles/fda-letter-caused-ptc-therapeutics-crash-today-2016-02-23", "https://www.nasdaq.com/articles/math-shows-qqq-can-go-129-2016-02-03", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vxf-lnkd-incy-bmrn-2016-01-28", "https://www.nasdaq.com/articles/will-2016-be-biomarin-pharmaceuticals-best-year-yet-2016-01-27", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-plunges-briefing-documents-acorda-buy-biotie-2016-01-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-viab-2016-01-19", "https://www.nasdaq.com/articles/sarepta-tanks-eteplirsen-briefing-document-raises-concerns-2016-01-18", "https://www.nasdaq.com/articles/midday-update-stocks-free-falling-following-more-bad-news-out-china-new-drop-oil-prices", "https://www.nasdaq.com/articles/why-medivation-inc-shares-crashed-32-january-2016-02-03", "https://www.nasdaq.com/articles/sarepta-therapeutics-plummets-50-fda-rejects-biomarins-nda-duchenne-muscular-dystrophy", "https://www.nasdaq.com/articles/close-update-stocks-close-lower-third-straight-week-china-oil-weighs-2016-01-15", "https://www.nasdaq.com/articles/update-sarepta-therapeutics-plummets-muted-fda-briefing-ahead-dmd-drug-review-2016-01-15", "https://www.nasdaq.com/articles/biomarins-dmd-drug-kyndrisa-receives-crl-from-the-fda-2016-01-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-ntap-2016-01-14", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-ionis-pharmaceuticals-inc-and-immunogen-inc-got-clobbered", "https://www.nasdaq.com/articles/fdas-change-heart-sends-sarepta-therapeutics-shares-soaring-2015-2016-01-13", "https://www.nasdaq.com/articles/heres-why-sarepta-therapeutics-getting-crushed-today-2016-01-15", "https://www.nasdaq.com/articles/biomarin-reveals-interim-data-from-pompe-disease-study-2016-01-12", "https://www.nasdaq.com/articles/what-does-2016-hold-biotech-stocks-2016-01-03", "https://www.nasdaq.com/articles/sareptas-dmd-drug-eteplirsen-to-face-fda-panel-in-january-2015-12-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-nclh-2015-12-29", "https://www.nasdaq.com/articles/vxf-lnkd-incy-bmrn-etf-inflow-alert-2015-12-28", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-actelion-amgen-gilead-abbvie-and-biomarin-2015-12-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-kalobios-removes-ceo-shkreli-actelion-pah-drug-approved-2015-12-23", "https://www.nasdaq.com/articles/3-biotechs-major-catalysts-incoming-2016-01-13", "https://www.nasdaq.com/articles/biomarins-bmrn-kyndrisa-review-period-extended-by-fda-2015-12-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-vrsk-bmrn-2015-12-18", "https://www.nasdaq.com/articles/why-shares-catalyst-pharmaceuticals-soared-today-2015-12-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-hikes-first-quarter-dividend-ariad-lowers-iclusig-outlook-2015", "https://www.nasdaq.com/articles/pbe-bmrn-incy-vrtx-large-outflows-detected-etf-2015-12-10", "https://www.nasdaq.com/articles/3-stocks-were-ready-sell-2015-12-06", "https://www.nasdaq.com/articles/why-failure-biomarin-caused-sareptas-shares-spike-53-november-2015-12-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-cmcsa-aal-2015-12-21", "https://www.nasdaq.com/articles/sarepta-therapeutics-discretion-better-part-valor-2015-11-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-gmcr-2015-11-25", "https://www.nasdaq.com/articles/biotech-stock-roundup-kalobios-soars-shkreli-steps-fda-panel-not-convinced-about-biomarin", "https://www.nasdaq.com/articles/pre-market-most-active-nov-25-2015-sune-sdrl-alu-pbr-tvix-de-kbio-xiv-mt-fb-aapl-bmrn-2015", "https://www.nasdaq.com/articles/health-care-sector-update-11252015-epix-bmrn-ipxl-2015-11-25", "https://www.nasdaq.com/articles/biomarins-bmrn-kyndrisa-fails-to-impress-fda-panel-2015-11-25", "https://www.nasdaq.com/articles/biomarins-vimizim-gets-nice-recommendation-in-england-2015-11-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biomarin-amgen-vertex-gilead-biogen-and-repros-2015-11", "https://www.nasdaq.com/articles/biomarins-dmd-drug-faces-obstacles-tomorrow-2015-11-23", "https://www.nasdaq.com/articles/if-youre-your-50s-consider-buying-these-stocks-2015-11-23", "https://www.nasdaq.com/articles/3-specialty-drug-makers-trying-spark-investor-interest-are-they-buys-2015-11-22", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-soaring-today-2015-11-20", "https://www.nasdaq.com/articles/pre-market-most-active-nov-20-2015-s-azn-srpt-mfg-ment-nmbl-auo-bmrn-ul-depo-kbio-qqq-2015", "https://www.nasdaq.com/articles/health-care-sector-update-11202015-srptbmrnkbioapto-2015-11-20", "https://www.nasdaq.com/articles/notable-thursday-option-activity-gty-bmrn-invn-2015-11-19", "https://www.nasdaq.com/articles/biomarin-down-on-fdas-briefing-document-on-kyndrisa-2015-11-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-clovis-plunges-label-expansion-gileads-harvoni-2015-11-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-jd-2015-11-12", "https://www.nasdaq.com/articles/sarepta-posts-wider-than-expected-loss-in-q3-shares-down-2015-11-06", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-earnings-pushing-toward-profitability-2015-11-01", "https://www.nasdaq.com/articles/biomarins-q3-loss-narrower-than-expected-outlook-revised-2015-10-30", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-29-2015-sbux-bidu-lnkd-ea-bxp-bmrn-rsg-ess-expe-fe-emn", "https://www.nasdaq.com/articles/what-awaits-biomarin-bmrn-this-earnings-season-2015-10-27", "https://www.nasdaq.com/articles/sareptas-long-term-phase-iib-data-on-eteplirsen-published-2015-11-18", "https://www.nasdaq.com/articles/ultragenyx-rare-reports-positive-interim-data-on-ux007-2015-10-20", "https://www.nasdaq.com/articles/biomarins-drisapersen-to-be-reviewed-by-fdas-committee-2015-10-19", "https://www.nasdaq.com/articles/ptc-therapeutics-presents-phase-iii-data-on-translarna-2015-10-16", "https://www.nasdaq.com/articles/why-biomarin-unfazed-price-gouging-proposals-2015-10-15", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vxf-ilmn-ual-bmrn-2015-10-15", "https://www.nasdaq.com/articles/health-care-sector-update-10152015-kite-bmrn-crbp-2015-10-15", "https://www.nasdaq.com/articles/sarepta-down-eteplirsen-likely-to-face-fda-panel-in-jan-2015-10-15", "https://www.nasdaq.com/articles/3-cancer-companies-watch-closely-2016-2015-10-20", "https://www.nasdaq.com/articles/biomarin-presents-data-on-vosoritide-at-medical-meeting-2015-10-13", "https://www.nasdaq.com/articles/catalyst-starts-congenital-myasthenic-syndromes-study-2015-10-07", "https://www.nasdaq.com/articles/sarepta-therapeutics-vs-biomarin-pharmaceutical-which-company-will-win-dmd-race-2015-10-06", "https://www.nasdaq.com/articles/biomarin-bmrn-to-acquire-rights-to-phenylketonuria-drugs-2015-10-02", "https://www.nasdaq.com/articles/sarepta-unveils-new-phase-iib-eteplirsen-data-shares-soar-2015-10-02", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-shares-are-soaring-today-2015-10-01", "https://www.nasdaq.com/articles/biomarin-bmrn-looks-good%3A-stock-adds-8.8-in-session-2015-10-01", "https://www.nasdaq.com/articles/how-biotech-stock-hopes-become-more-one-trick-pony-2015-10-14", "https://www.nasdaq.com/articles/duchenne-muscular-dystrophy-patent-battle-continues-2015-09-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-intc-2015-09-28", "https://www.nasdaq.com/articles/bull-day-medivation-mdvn-2015-09-24", "https://www.nasdaq.com/articles/bmrn-crosses-below-key-moving-average-level-2015-09-22", "https://www.nasdaq.com/articles/biomarin-dr.-reddys-agree-to-settle-kuvan-patent-litigation-2015-09-21", "https://www.nasdaq.com/articles/medivation-upgraded-to-strong-buy-perfect-for-your-portfolio-2015-09-15", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vxf-ilmn-bmrn-lnkd-2015-09-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-mat-wdc-2015-09-30", "https://www.nasdaq.com/articles/first-week-april-2016-options-trading-biomarin-pharmaceutical-inc-bmrn-2015-08-28", "https://www.nasdaq.com/articles/duchenne-muscular-dystrophy-race-2015-08-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-vital-therapies-amgen-biomarin-acorda-and-macrocure", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vxf-ilmn-bmrn-lnkd-2015-08-26", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-gains-patent-issues-vital-crushed-liver-data-2015-08-26", "https://www.nasdaq.com/articles/sareptas-dmd-drug-eteplirsen-gains-fda-priority-review-2015-08-26", "https://www.nasdaq.com/articles/medivation-to-gain-global-rights-to-biomarins-talazoparib-2015-08-25", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vxf-ilmn-bmrn-lnkd-2015-09-03", "https://www.nasdaq.com/articles/3-biotech-stocks-could-be-buyout-targets-2015-08-21", "https://www.nasdaq.com/articles/united-therapeutics-to-sell-priority-review-voucher-to-abbvie-2015-08-20", "https://www.nasdaq.com/articles/biomarins-drisapersen-gets-rare-pediatric-disease-status-2015-08-20", "https://www.nasdaq.com/articles/vanguard-extended-market-etf-experiences-big-inflow-2015-08-18", "https://www.nasdaq.com/articles/are-3-best-performing-big-cap-biotech-stocks-2015-still-worth-buying-2015-08-17", "https://www.nasdaq.com/articles/5-most-expensive-drugs-world-2015-2015-08-15", "https://www.nasdaq.com/articles/sarepta-posts-narrower-than-expected-loss-in-q2-shares-up-analyst-blog-2015-08-07", "https://www.nasdaq.com/articles/biomarins-big-bet-muscular-dystrophy-already-paying-2015-08-22", "https://www.nasdaq.com/articles/biomarin-q2-loss-narrower-than-expected-maintains-outlook-analyst-blog-2015-08-04", "https://www.nasdaq.com/articles/biomarin-pharmaceuticals-lumpy-sales-strike-again-2015-08-03", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-3-2015-aig-all-ggp-bmrn-vno-xl-ctrp-mchp-cyh-mic-ohi", "https://www.nasdaq.com/articles/will-biomarin-top-q2-earnings-again-on-vimizim-sales-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/vanguard-extended-market-etf-experiences-big-outflow-2015-07-30", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bmrn-might-surprise-this-earnings-season-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/will-amgen-amgn-keep-earnings-streak-alive-2q-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-avgo-regn-2015-08-04", "https://www.nasdaq.com/articles/after-hours-most-active-jul-24-2015-ntct-qqq-tdw-t-bmrn-aapl-utxa-ge-ne-csco-plcm-rdn-2015", "https://www.nasdaq.com/articles/biomarin-provides-update-on-phase-ii-talazoparib-study-analyst-blog-2015-07-21", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-vxf-ilmn-lnkd-bmrn-2015-07-20", "https://www.nasdaq.com/articles/catabasis-up-on-fast-track-status-for-dmd-drug-cat-1004-analyst-blog-2015-07-07", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-celgene-juno-therapeutics-intercept-biomarin-and", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-celgene-immunotherapy-deal-biomarinsarepta-dmd-drugs-progress", "https://www.nasdaq.com/articles/sarepta-files-eteplirsen-nda-secures-%2440m-debt-financing-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/will-vertex-vrtx-surprise-lower-loss-q2-analyst-blog-2015-07-28", "https://www.nasdaq.com/articles/biomarin-dmd-drug-drisapersen-validated-for-eu-review-analyst-blog-2015-06-26", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-biomarin-vical-epizyme-amgen-and-medicines-co-press", "https://www.nasdaq.com/articles/biotech-stock-roundup-biomarin-jumps-dwarfism-data-vical-plunges-vaccine-data-analyst-blog", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-pth-2015-06-19", "https://www.nasdaq.com/articles/health-care-sector-update-06192015-achc-bmrn-cytk-2015-06-19", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-surges-on-price-target-increase-analyst-blog-2015-06-19", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-shares-are-jumping-higher-2015-06-18", "https://www.nasdaq.com/articles/biomarins-nda-for-dmd-drug-drisapersen-accepted-by-fda-analyst-blog-2015-06-30", "https://www.nasdaq.com/articles/health-care-sector-update-06182015-bmrn-dsci-parn-2015-06-18", "https://www.nasdaq.com/articles/mid-afternoon-market-update-biomarin-pharmaceutical-jumps-following-announcement-positive", "https://www.nasdaq.com/articles/thursdays-etf-movers-pbe-oih-2015-06-18", "https://www.nasdaq.com/articles/mid-day-market-update-oracle-drops-downbeat-results-radius-health-shares-surge-2015-06-18", "https://www.nasdaq.com/articles/use-options-chance-buy-bmrn-30-discount-2015-06-16", "https://www.nasdaq.com/articles/biomarin-seeks-eu-approval-for-dmd-drug-drisapersen-analyst-blog-2015-06-09", "https://www.nasdaq.com/articles/these-3-ultra-rare-diseases-are-utterly-terrifying-2015-06-07", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-kroger-earnings-beat-views-2015-06-18", "https://www.nasdaq.com/articles/retrophin-soars-on-%24245m-priority-review-voucher-sale-analyst-blog-2015-05-28", "https://www.nasdaq.com/articles/wednesdays-etf-movers-bbh-xop-2015-05-27", "https://www.nasdaq.com/articles/did-biomarin-bet-wrong-experimental-dmd-drug-2015-05-27", "https://www.nasdaq.com/articles/merck-kgaa-biomarins-kuvan-may-undergo-label-update-analyst-blog-2015-05-26", "https://www.nasdaq.com/articles/uh-oh-billionaire-george-soros-just-stepped-another-biotech-landmine-2015-05-24", "https://www.nasdaq.com/articles/sarepta-to-finish-eteplirsen-regulatory-filing-by-mid-15-analyst-blog-2015-05-20", "https://www.nasdaq.com/articles/why-shares-sarepta-therapeutics-skyrocketed-today-2015-05-20", "https://www.nasdaq.com/articles/pfizers-monstrous-clinical-pipeline-harboring-2-hidden-gems-2015-05-30", "https://www.nasdaq.com/articles/forget-gilead-sciences-inc-tiny-biotech-offers-much-richer-opportunity-2015-05-12", "https://www.nasdaq.com/articles/will-suitors-line-buy-these-biotech-stocks-next-2015-05-10", "https://www.nasdaq.com/articles/sarepta-posts-wider-than-expected-loss-eteplirsen-in-focus-analyst-blog-2015-05-08", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn%3A-strong-industry-solid-earnings-estimate-revisions-tale-of", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-shares-soared-today-2015-05-06", "https://www.nasdaq.com/articles/integra-lifesciences-tops-q1-earnings-revenues-view-up-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/acorda-posts-1q-loss-ampyra-generic-challenges-focus-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/why-im-buying-sarepta-therapeutics-stock-2015-05-20", "https://www.nasdaq.com/articles/could-dark-horse-be-pfizer-incs-next-major-acquisition-2015-05-02", "https://www.nasdaq.com/articles/hot-issues-biomarin-pharmaceutical-inc-earnings-conference-call-2015-05-01", "https://www.nasdaq.com/articles/sanofi-misses-on-q1-earnings-by-a-penny-maintains-outlook-analyst-blog-2015-05-01", "https://www.nasdaq.com/articles/geron-q1-loss-in-line-with-estimates-restructuring-on-track-analyst-blog-2015-05-01", "https://www.nasdaq.com/articles/biomarin-q1-loss-narrower-than-expected-15-view-revised-analyst-blog-2015-05-01", "https://www.nasdaq.com/articles/earnings-reaction-history-biomarin-pharmaceutical-333-follow-through-indicator-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-april-30-2015-gild-v-aig-psa-lnkd-bmrn-swks-flt-emn-expe-wu", "https://www.nasdaq.com/articles/alkermes-q1-loss-narrower-than-expected-maintains-view-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-wednesday-tale-of-the-tape-2015-04-29", "https://www.nasdaq.com/articles/biomarin-upgraded-to-strong-buy-is-it-in-your-portfolio-analyst-blog-2015-04-29", "https://www.nasdaq.com/articles/can-expedia-expe-pull-a-surprise-this-earnings-season-analyst-blog-2015-04-29", "https://www.nasdaq.com/articles/will-biomarin-bmrn-top-earnings-again-on-vimzim-sales-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/will-united-therapeutics-uthr-miss-this-earnings-season-analyst-blog-2015-04-27", "https://www.nasdaq.com/articles/10-largest-companies-market-cap-biotech-2015-04-11", "https://www.nasdaq.com/articles/why-1-wall-street-firm-thinks-biomarin-pharmaceutical-inc-could-soar-2015-04-10", "https://www.nasdaq.com/articles/3-things-watch-biomarin-pharmaceutical-inc-reports-earnings-2015-04-29", "https://www.nasdaq.com/articles/midcap-growth-funds-power-ahead-amid-march-malaise-2015-04-07", "https://www.nasdaq.com/articles/sarepta-therapeutics-incs-ceo-exits-stock-now-buy-2015-04-01", "https://www.nasdaq.com/articles/sarepta-ceo-exits-eteplirsen-regulatory-filing-on-track-analyst-blog-2015-04-01", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shows-strength%3A-stock-up-11.5-tale-of-the-tape-2015-03-30", "https://www.nasdaq.com/articles/healthcare-merger-monday-these-3-stocks-could-be-healthcares-next-buyout-targets-2015-03", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-stock-surging-today-2015-03-27", "https://www.nasdaq.com/articles/pre-market-most-active-mar-27-2015-bbry-dow-nvo-sap-sdrl-orex-xiv-scai-aapl-tpvg-mt-bmrn", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-larger-sp-500-component-omnicom-group-2015-04-10", "https://www.nasdaq.com/articles/friday-sector-leaders-general-contractors-builders-drugs-2015-03-27", "https://www.nasdaq.com/articles/use-options-chance-buy-bmrn-28-discount-2015-03-26", "https://www.nasdaq.com/articles/profit-takers-active-biotech-stalls-2015-03-24", "https://www.nasdaq.com/articles/health-care-sector-update-03172015-cldx-bmrn-icpt-2015-03-17", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-jumps%3A-stock-moves-up-6.9-tale-of-the-tape-2015-03-16", "https://www.nasdaq.com/articles/fridays-etf-movers-pbe-pin-2015-03-13", "https://www.nasdaq.com/articles/3-easy-ways-fail-when-investing-biotech-stocks-2015-03-08", "https://www.nasdaq.com/articles/fridays-etf-movers-fbt-xop-2015-03-27", "https://www.nasdaq.com/articles/did-researchers-just-discover-functional-cure-duchenne-muscular-dystrophy-2015-03-01", "https://www.nasdaq.com/articles/company-news-for-february-27-2015-corporate-summary-2015-02-27", "https://www.nasdaq.com/articles/actavis-infectious-disease-product-avycaz-gets-fda-nod-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/amgen-reports-encouraging-late-stage-data-on-amg-416-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/medivation-beats-on-q4-earnings-revenues-xtandi-soars-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/merge-healthcare-mrge-q4-earnings-up-y-y-revenues-miss-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/biomarins-q4-loss-narrower-than-expected-gives-2015-view-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/first-trust-health-care-alphadex-fund-experiences-big-inflow-2015-03-03", "https://www.nasdaq.com/articles/use-options-chance-buy-bmrn-32-discount-2015-02-25", "https://www.nasdaq.com/articles/alkermes-falls-on-pipeline-news-q4-earnings-plunge-y-y-analyst-blog-2015-02-25", "https://www.nasdaq.com/articles/profitability-sight-biomarin-pharmaceutical-inc-2015-02-25", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-25-2015-crm-avgo-lb-bmrn-cxo-ar-wday-mdvn-esv-teg", "https://www.nasdaq.com/articles/earnings-reaction-history-biomarin-pharmaceutical-333-follow-through-indicator-27", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-25-2015-crm-avgo-lb-bmrn-cxo-ar-wday-mdvn-esv-teg-0", "https://www.nasdaq.com/articles/illumina-expands-ngs-portfolio-with-neoprep-library-system-analyst-blog-2015-02-24", "https://www.nasdaq.com/articles/orexigen-orex-misses-q4-earnings-contrave-impresses-analyst-blog-2015-02-26", "https://www.nasdaq.com/articles/celgene-gains-on-label-expansion-of-revlimid-in-the-eu-analyst-blog-2015-02-23", "https://www.nasdaq.com/articles/will-biomarin-bmrn-beat-estimates-this-earnings-season-analyst-blog-2015-02-23", "https://www.nasdaq.com/articles/celgene-up-on-hematology-drug-revlimids-label-expansion-analyst-blog-2015-02-20", "https://www.nasdaq.com/articles/coronado-biosciences-in-licenses-revogenexs-pain-drug-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/regenerons-eylea-tops-diabetic-macular-edema-study-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/seattle-genetics-sgen-filed-supplemental-bla-for-adcetris-analyst-blog-2015-02-19", "https://www.nasdaq.com/articles/seattle-genetics-sea-cd40-enters-phase-i-for-solid-tumors-analyst-blog-2015-02-18", "https://www.nasdaq.com/articles/eli-lillys-bil-filing-delayed-baricitinib-scores-phase-iii-analyst-blog-2015-02-24", "https://www.nasdaq.com/articles/actelions-aliof-earnings-revenues-fall-y-y-in-q4-analyst-blog-2015-02-17", "https://www.nasdaq.com/articles/synthetic-biologics-syn-jumps%3A-stock-up-9.2-tale-of-the-tape-2015-02-17", "https://www.nasdaq.com/articles/astrazenecas-patent-for-pulmicort-respules-found-invalid-analyst-blog-2015-02-16", "https://www.nasdaq.com/articles/emergent-biosolutions-reports-positive-data-on-biothrax-analyst-blog-2015-02-16", "https://www.nasdaq.com/articles/company-big-winner-obamas-push-precision-medicine-2015-02-14", "https://www.nasdaq.com/articles/acorda-beats-q4-earnings-estimates-ampyra-sales-grow-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/oncolytics-reolysin-gets-orphan-status-for-ovarian-cancer-analyst-blog-2015-02-12", "https://www.nasdaq.com/articles/oncolytics-reolysin-gets-another-orphan-drug-status-analyst-blog-2015-02-18", "https://www.nasdaq.com/articles/genomic-health-loss-narrower-than-expected-revenues-lag-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/seattle-genetics-posts-narrower-than-expected-loss-in-q4-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/isis-pharma-to-get-%245m-from-biogen-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/synthetic-biologics-unveils-phase-ib-safety-data-on-syn-004-analyst-blog-2015-02-11", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-february-2015-02-02", "https://www.nasdaq.com/articles/8-billion-hedge-fund-bought-extremely-risky-stock-should-you-2015-02-01", "https://www.nasdaq.com/articles/synageva-starts-dosing-in-phase-i-ii-study-for-sanfilippo-b-analyst-blog-2015-01-28", "https://www.nasdaq.com/articles/amgens-skin-cancer-drug-to-face-fda-advisory-panel-analyst-blog-2015-02-12", "https://www.nasdaq.com/articles/forget-marijuana-stocks-here-are-3-smarter-investments-2015-01-24", "https://www.nasdaq.com/articles/health-care-sector-update-01222015-shpg-nnvc-bmrn-2015-01-22", "https://www.nasdaq.com/articles/biomarin-to-raise-funds-to-finance-prosensa-acquisition-analyst-blog-2015-01-22", "https://www.nasdaq.com/articles/state-union-address-investing-idea-precision-medicine-2015-01-21", "https://www.nasdaq.com/articles/3-warning-signs-youve-invested-dangerous-biotech-stock-2015-01-17", "https://www.nasdaq.com/articles/biomarin-gains-on-vimizim-2014-view-batten-disease-data-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/3-biotech-stocks-focused-curing-ultra-rare-diseases-2015-01-11", "https://www.nasdaq.com/articles/use-options-chance-buy-bmrn-24-discount-2015-01-27", "https://www.nasdaq.com/articles/biomarins-vimizim-okd-in-japan-for-morquio-a-syndrome-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/ibb-gild-regn-bmrn-large-inflows-detected-etf-2014-12-29", "https://www.nasdaq.com/articles/health-care-sector-update-12262014-bmrnrnatpirhhby-2014-12-26", "https://www.nasdaq.com/articles/twitters-favorite-biotech-and-pharma-stocks-2014-12-16", "https://www.nasdaq.com/articles/5-biotech-stocks-buy-2015-2014-12-09", "https://www.nasdaq.com/articles/3-biotech-companies-are-making-incredibly-smart-moves-2014-12-08", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biomarin-to-acquire-prosensa-abbvie-hcv-therapy-closer-to-eu", "https://www.nasdaq.com/articles/why-sarepta-therapeutics-inc-stock-tumbled-15-december-2015-01-09", "https://www.nasdaq.com/articles/biomarins-vimizim-okd-in-japan-for-morquio-a-syndrome-analyst-blog-2014-12-30", "https://www.nasdaq.com/articles/midday-update-stocks-grind-cautiously-higher-ahead-economic-data-gains-europe-2014-11-24", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-biomarin-acquire-prosensa-1775share-2014-11", "https://www.nasdaq.com/articles/us-stock-futures-buoyed-upbeat-german-data-strength-eurozone-stimulus-talk-2014-11-24", "https://www.nasdaq.com/articles/gilead-sciences-inc-just-paid-125-million-something-it-cant-use-year-2014-11-24", "https://www.nasdaq.com/articles/closing-update-stocks-extend-winning-streak-third-day-2014-11-24", "https://www.nasdaq.com/articles/health-care-sector-update-11262014-srptrnabmrnbdxmrge-2014-11-26", "https://www.nasdaq.com/articles/mid-afternoon-market-update-trina-solar-drops-after-quarterly-results-tetraphase", "https://www.nasdaq.com/articles/why-prosensa-holding-nv-stock-skyrocketed-2014-11-24", "https://www.nasdaq.com/articles/mid-day-market-update-dow-edges-lower-platinum-underwriters-shares-jump-acquisition-news", "https://www.nasdaq.com/articles/health-care-sector-update-11242014-synrnabmrntthitthto-2014-11-24", "https://www.nasdaq.com/articles/gilead-to-buy-knight-therapeutics-priority-review-voucher-analyst-blog-2014-11-20", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/will-catalyst-pharmaceuticals-cprx-loss-narrow-in-q3-analyst-blog-2014-11-12", "https://www.nasdaq.com/articles/health-care-sector-update-11242014-ttphatlnrhhbyrnabmrntthitthto-2014-11-24", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-inc-roared-14-higher-october-2014-11-05", "https://www.nasdaq.com/articles/5-most-expensive-drugs-world-2014-10-26", "https://www.nasdaq.com/articles/fridays-etf-unusual-volume-bbh-2014-10-24", "https://www.nasdaq.com/articles/biomarin-q3-loss-narrower-than-expected-view-raised-analyst-blog-2014-10-24", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-earnings-striving-be-blockbuster-company-2014-10-23", "https://www.nasdaq.com/articles/after-hours-earnings-report-october-23-2014-msft-amzn-cb-cern-pfg-klac-swn-ew-bmrn-tv-srcl", "https://www.nasdaq.com/articles/will-biomarin-bmrn-disappoint-this-earnings-season-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/trend-making-gilead-sciences-inc-worry-2014-11-05", "https://www.nasdaq.com/articles/january-2017-options-now-available-biomarin-pharmaceutical-bmrn-2014-09-15", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-bmrn-2014-09-05", "https://www.nasdaq.com/articles/merck-kgaas-kuvan-effective-in-under-4-year-olds-analyst-blog-2014-09-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-united-therapeutics-court-ruling-amgen-files-pcsk9-inhibitor-analyst", "https://www.nasdaq.com/articles/can-biomarin-pharmaceutical-bmrn-run-higher-on-strong-earnings-estimate-revisions-tale-of", "https://www.nasdaq.com/articles/7-things-regeneron-pharmaceuticals-incs-management-wants-you-know-2014-08-26", "https://www.nasdaq.com/articles/biomarin-bmrn-faces-threat-of-genericization-for-kuvan-analyst-blog-2014-09-25", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bmrn-could-beat-earnings-estimates-again-tale-of-the-tape-0", "https://www.nasdaq.com/articles/markets-end-july-undecided-2014-07-31", "https://www.nasdaq.com/articles/biomarin-q2-loss-narrower-than-expected-revenue-guidance-up-analyst-blog-2014-07-31", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-sovaldi-biogens-tecfidera-impressive-run-continues-analyst", "https://www.nasdaq.com/articles/incytes-jakafi-fails-to-provide-relief-in-polycythemia-vera-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/biogens-q2-earnings-surpass-expectations-tecfidera-shines-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/cubist-misses-q2-earnings-estimates-on-weak-cubicin-sales-analyst-blog-2014-07-23", "https://www.nasdaq.com/articles/nps-pharma-reports-earnings-in-q2-on-strong-gattex-sales-analyst-blog-2014-08-07", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2014-07-18", "https://www.nasdaq.com/articles/repros-gets-additional-fda-guidance-for-androxal-analyst-blog-2014-07-17", "https://www.nasdaq.com/articles/arena-pharmaceuticals-pain-candidate-gets-new-u.s.-patent-analyst-blog-2014-07-16", "https://www.nasdaq.com/articles/peregrine-pharmaceuticals-q4-loss-narrower-than-expected-analyst-blog-2014-07-15", "https://www.nasdaq.com/articles/will-johnson-johnson-jnj-beat-this-earnings-season-analyst-blog-2014-07-14", "https://www.nasdaq.com/articles/biomarins-vimizim-gets-canadian-nod-analyst-blog-2014-07-08", "https://www.nasdaq.com/articles/why-biomarin-pharmaceutical-bmrn-could-beat-earnings-estimates-again-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/bluebird-bio-inc.-blue-in-focus%3A-stock-surges-10.24-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/biomarins-pipeline-advances-analyst-blog-2014-05-29", "https://www.nasdaq.com/articles/loss-at-biomarin-narrower-than-expected-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/ibb-celg-vrtx-bmrn-large-inflows-detected-etf-2014-04-24", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-pdufa-date-pushed-out-alkermes-impresses-data-analyst-blog", "https://www.nasdaq.com/articles/good-news-for-biomarin-analyst-blog-2014-04-15", "https://www.nasdaq.com/articles/bbh-alks-bmrn-isis-large-outflows-detected-etf-2014-03-27", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-august-16th-2014-06-25", "https://www.nasdaq.com/articles/good-news-for-catalyst-pharma-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-catalyst-pharma-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-larger-sp-500-component-newmont-mining-2014-02-28", "https://www.nasdaq.com/articles/interesting-bmrn-put-and-call-options-october-18th-2014-02-26", "https://www.nasdaq.com/articles/biomarin-rises-on-favorable-chmp-opinion-analyst-blog-2014-02-21", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-eylea-impresses-gilead-files-next-hcv-drug-analyst-blog", "https://www.nasdaq.com/articles/strong-2014-sales-guidance-from-biomarin-analyst-blog-2014-02-19", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-shares-cross-below-200-dma-2014-03-27", "https://www.nasdaq.com/articles/biomarins-pipeline-encourages-analyst-blog-2014-01-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-sarepta-spikes-data-alnylam-deal-analyst-blog-2014-01-22", "https://www.nasdaq.com/articles/pipeline-progress-at-biomarin-analyst-blog-2014-01-15", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-catalyst-pharmaceutical-partners-rises-14", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-01-08-1", "https://www.nasdaq.com/articles/notice-of-allowance-received-by-alkermes-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-inc-bmrn-new-analyst-report-zacks-equity-research-zacks-equity", "https://www.nasdaq.com/articles/fda-clears-biomarins-vimizim-analyst-blog-2014-02-18", "https://www.nasdaq.com/articles/biomarin-seeks-canadian-approval-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-news-boosts-biogen-gilead-celgene-analyst-blog-2013-11-27", "https://www.nasdaq.com/articles/myriad-biomarin-collaborate-again-analyst-blog-2013-11-22", "https://www.nasdaq.com/articles/us-stocks-short-market-care-2013-11-21", "https://www.nasdaq.com/articles/fda-panel-positive-on-biomarins-vimizim-analyst-blog-2013-11-20", "https://www.nasdaq.com/articles/biomarin-shoots-up-ahead-of-fda-panel-analyst-blog-2013-11-18", "https://www.nasdaq.com/articles/biomarin-pharmaceutical-bmrn-in-focus%3A-stock-jumps-7.7-tale-of-the-tape-2013-11-18", "https://www.nasdaq.com/articles/myriad-janssen-partner-on-bracanalysis-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/loss-at-biomarin-wider-than-expected-analyst-blog-2013-10-25", "https://www.nasdaq.com/articles/sector-update-healthcare-higher-pre-market-immunogen-spikes-7-earnings-2013-10-25", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-10-25-1", "https://www.nasdaq.com/articles/4-pharma-stocks-set-to-deliver-earnings-surprises-earnings-esp-2013-10-22", "https://www.nasdaq.com/articles/is-eli-lilly-lly-poised-to-beat-earnings-estimates-analyst-blog-2013-10-21", "https://www.nasdaq.com/articles/is-forest-labs-frx-poised-to-beat-earnings-estimates-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/good-news-for-catalyst-pharmas-pipeline-analyst-blog-2013-10-16", "https://www.nasdaq.com/articles/pre-market-most-active-nov-15-2013-tmus-nok-smfg-bac-vnda-bmrn-pfe-met-slm-mhld-agnc-csco", "https://www.nasdaq.com/articles/encouraging-pipeline-data-from-biomarin-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/pipeline-progress-at-biomarin-analyst-blog-2013-09-24", "https://www.nasdaq.com/articles/market-primer-friday-september-20-us-markets-fall-investors-re-evaluate-2013-09-20", "https://www.nasdaq.com/articles/sector-update-healthcare-flat-higher-pre-market-isis-4-2013-09-19", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-19-0", "https://www.nasdaq.com/articles/pre-market-most-active-sep-19-2013-rad-nok-orcl-bmrn-p-sny-onxx-fsc-csco-fb-drys-2013-09", "https://www.nasdaq.com/articles/pipeline-update-from-biomarin-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/biomarin-to-raise-funds-analyst-blog-2013-10-08", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-17-0", "https://www.nasdaq.com/articles/catalyst-pharma-raises-funds-analyst-blog-2013-09-11", "https://www.nasdaq.com/articles/fda-designation-for-cprxs-firdapse-analyst-blog-2013-08-28", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-biomarin-analyst-blog-2013-07-26", "https://www.nasdaq.com/articles/after-hours-earnings-report-july-25-2013-amzn-gild-sbux-mck-cb-cern-nem-rsg-pfg-klac-bmrn", "https://www.nasdaq.com/articles/biomarin-stays-neutral-analyst-blog-2013-07-08", "https://www.nasdaq.com/articles/biomarin-files-vimizim-ma-in-brazil-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/healthcare-stocks-mixed-near-bell-biomarin-pharma-climbing-morquio-treatment-set-fda", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-rise-cracker-barrel-posts-upbeat-earnings-2013-06-03", "https://www.nasdaq.com/articles/biomarin-widens-loss-maintains-view-analyst-blog-2013-04-29", "https://www.nasdaq.com/articles/biomarin-attains-52-week-high-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/biomarin-files-cta-for-bmn-190-analyst-blog-2013-04-03", "https://www.nasdaq.com/articles/bmrn-seeks-us-approval-of-vimizim-analyst-blog-2013-04-02", "https://www.nasdaq.com/articles/data-on-biomarins-bmn-701-analyst-blog-2013-03-21", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-inc-regn-todays-most-compelling-buy-2013-03-14", "https://www.nasdaq.com/articles/mid-day-market-update-markets-turn-mixed-colonial-properties-gains-acquisition-news-2013", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-21-2013-aig-hpq-psa-nem-intu-swn-cog-jwn-sbac-mhk", "https://www.nasdaq.com/articles/positive-data-from-bmrns-pku-016-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/biomarin-takes-over-zacharon-analyst-blog-2013-01-10", "https://www.nasdaq.com/articles/biomarin-strategy-looks-further-gains-2012-12-11", "https://www.nasdaq.com/articles/weekly-top-insider-sells-aapl-gild-bmrn-and-pcln-2012-11-19", "https://www.nasdaq.com/articles/good-news-for-biomarin-analyst-blog-2012-11-06", "https://www.nasdaq.com/articles/pre-market-most-active-nov-5-2012-bac-qqq-aapl-bmrn-gfa-bhp-fb-ubs-rig-nok-znga-intc-2012", "https://www.nasdaq.com/articles/biomarin-reports-wider-loss-analyst-blog-2013-02-22", "https://www.nasdaq.com/articles/after-hours-earnings-report-february-21-2013-aig-hpq-psa-nem-intu-swn-cog-jwn-sbac-mhk", "https://www.nasdaq.com/articles/positive-data-from-bmrns-pku-016-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/biomarin-progresses-with-peg-pa-analyst-blog-2012-09-27", "https://www.nasdaq.com/articles/4-biotech-stocks-ready-explode-2012-09-06", "https://www.nasdaq.com/articles/biomarin-loss-widens-sales-climb-analyst-blog-2012-08-02", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-1-2012-dox-bmrn-apl-algt-alex-aat-sam-atni-ain-asi-axti", "https://www.nasdaq.com/articles/why-volatility-key-trade-biomarin-2012-07-11", "https://www.nasdaq.com/articles/biomarin-reports-narrower-loss-analyst-blog-2012-10-26", "https://www.nasdaq.com/articles/biomarin-to-raise-funds-analyst-blog-2012-05-31", "https://www.nasdaq.com/articles/myriad-inks-deal-with-cephalon-analyst-blog-2012-04-02", "https://www.nasdaq.com/articles/biomarin-raised-to-neutral-analyst-blog-2012-03-14", "https://www.nasdaq.com/articles/loss-at-biomarin-wider-than-expected-analyst-blog-2012-02-17", "https://www.nasdaq.com/articles/biomarin-lowered-to-underperform-analyst-blog-2012-02-15", "https://www.nasdaq.com/articles/zacks-bull-and-bear-of-the-day-highlights%3A-proassurance-biomarin-pharmaceutical-diebold", "https://www.nasdaq.com/articles/zacks-5-rank-additions-for-wednesday-tale-of-the-tape-2012-02-08", "https://www.nasdaq.com/articles/biomarin-prices-share-offering-analyst-blog-2012-06-01", "https://www.nasdaq.com/articles/biomarins-facility-expansion-backed-analyst-blog-2011-12-22", "https://www.nasdaq.com/articles/pipeline-progress-at-biomarin-analyst-blog-2011-12-01", "https://www.nasdaq.com/articles/facility-expansion-at-biomarin-analyst-blog-2011-11-29", "https://www.nasdaq.com/articles/narrowing-down-list-biotech-etfs-2-wed-recommend-2011-06-22", "https://www.nasdaq.com/articles/qiagen-expands-with-new-deals-analyst-blog-2012-01-12"], "Content": []}